Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Clinical Microbiology Reviews
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
ARTICLE

Treatment of Giardiasis

Timothy B. Gardner, David R. Hill
Timothy B. Gardner
Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Hill
Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CMR.14.1.114-128.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

SUMMARY

SUMMARY Giardia lamblia is both the most common intestinal parasite in the United States and a frequent cause of diarrheal illness throughout the world. In spite of its recognition as an important human pathogen, there have been relatively few agents used in therapy. This paper discusses each class of drugs used in treatment, along with their mechanism of action, in vitro and clinical efficacy, and side effects and contraindications. Recommendations are made for the preferred treatment in different clinical situations. The greatest clinical experience is with the nitroimidazole drugs, i.e., metronidazole, tinidazole, and ornidazole, which are highly effective. A 5- to 7-day course of metronidazole can be expected to cure over 90% of individuals, and a single dose of tinidazole or ornidazole will cure a similar number. Quinacrine, which is no longer produced in the United States, has excellent efficacy but may be poorly tolerated, especially in children. Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days. Paromomycin may be used during early pregnancy, because it is not systematically absorbed, but it is not always effective. Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine.

Giardia lamblia, also called Giardia duodenalis or Giardia intestinalis, is a protozoan parasite of the small intestine that causes extensive morbidity worldwide. It was first described in the late 17th century by the Dutch microscopist Antonie van Leeuwenhoek62, and research into its epidemiology, pathogenesis, and treatment has intensified since G. lambliawaterborne outbreaks were reported in Europe and the United States during the 1960s and 1970s 53, 81, 123, 128, 174.Giardia infects approximately 2% of the adults and 6 to 8% of the children in developed countries worldwide and is currently responsible for the largest number of waterborne outbreaks of diarrhea in the United States 54, 139.

Despite the recognition of G. lamblia clinical illness for the last 40 years, the nearly 5,000 people hospitalized with giardiasis annually in the United States 149, and the millions infected worldwide, there have been few reviews of therapy for this infection and no definitive treatment protocols have been published58, 113, 150, 165, 261. In addition, only a handful of agents have been used in therapy, and the agents which are available may have adverse effects or be contraindicated in certain clinical situations. Also, resistance may play a role in some infections. This paper will review the agents currently used for the treatment of giardiasis. The history, mechanism of action, in vitro and clinical studies, and adverse effects are detailed for each drug class. In addition, special clinical situations are discussed and recommendations for therapy are made.

BACKGROUND

The life cycle of G. lamblia has two forms: the trophozoite (Fig. 1) and the cyst. The cyst is the infectious form and is ingested in contaminated water or food or directly from fecal-oral contact. As few as 10 cysts may establish infection 206. After ingestion, excystation occurs. Excystation is thought to be initiated by contact with acidic gastric contents, followed by a highly coordinated sequence of events leading to the release of one or two trophozoites 27, 109, 210. A parasite-derived protease may be activated during the excystation process 252. The trophozoite infects the duodenum and upper intestine, which have a favorable alkaline pH, and gives rise to the clinical sequelae. As trophozoites pass through the small intestine to the colon, encystation occurs. Encystation can be initiated in vitro by culture of parasites in a reduced concentration of bile salts and cholesterol followed by culture in an increased concentration of bile at an alkaline pH 156. Cyst wall proteins are then transcribed, secreted into encystment-specific vesicles, and transported to the newly forming cell wall over 14 to 16 h 75.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Ventral surface of a Giardia lambliatrophozoite imaged by scanning electron microscopy. It demonstrates the disk and flagella. A second trophozoite is seen behind it. Magnification, ×8,100. Photo courtesy of David Dorward, Rocky Mountain Laboratory, National Institutes of Health, Hamilton, Mont.

The wide variety of clinical presentations, from severe disease to an asymptomatic carrier state, makes the definitive determination of pathogenesis difficult. However, several theories have been put forward83, 115. Some of the most likely include the ability of the protozoan to cause direct damage to the intestinal mucosa via adherence with the disk, disaccharidase enzyme reduction following brush border damage, the release from Giardia of cytopathic substances such as thiol proteinases and lectins, and the stimulation of a host immune response with release of cytokines and mucosal inflammation 41, 48, 61, 78, 83, 106, 110, 157, 259. Additionally, it is likely that there are genetic differences betweenGiardia isolates which may confer virulence 115, 173, 182, 190. The surface of Giardia may also undergo antigenic variation in the human host and thus evade immune detection181. Given these multiple potential mechanisms, a multifactoral process is likely.

G. lamblia is found primarily in mammals including humans, cats, dogs, beavers, and cattle 40, 74, 77, 257. Transmission of the G. lamblia cyst to humans occurs most commonly following ingestion of contaminated water 139. Transmission via surface water is facilitated by the relative resistance of the cyst to chlorination and its ability to survive in cold water for weeks 59, 122. Transmission by food 22, 152, 187, by direct fecal-oral contact among children in day care 28, 224, 237 or in developing-world settings 96, 159, and by sexual practices which include oral-anal contact 168 represent other common modes of transmission 113. G. lamblia is also seen as a cause of prolonged diarrhea in travelers 37, 66, 125, 136, 205; N. Fiumara, Letter, N. Engl. J. Med.288:1410–1411, 1973).

Worldwide, the majority of patients infected with G. lamblia are asymptomatic. However, typical clinical symptoms of giardiasis usually begin 1 to 3 weeks after ingestion of cysts and are marked by diarrhea, malaise, flatulence, greasy stools, and abdominal cramps 113, 256. Other symptoms commonly include bloating, weight loss 174, and anorexia. Vomiting and fever are less common, and blood- or mucus-tinged feces are rare. Illness can last several months if untreated and can be characterized by continued exacerbations of diarrheal symptoms. With chronic illness, malabsorption of fat, lactose, vitamin A, and vitamin B12are reported, and failure of children to thrive has been noted86, 112, 149, 184, 227.

Giardiasis should be considered in the differential diagnosis of many diarrheal syndromes. A careful history, which notes any risk factors such as recent travel, wilderness exposure, or situations involving poor fecal-oral hygiene, and a physical examination are essential. Infection with G. lamblia can often be distinguished from bacterial and viral infections because of the longer duration of illness, 7 to 10 days by the time of presentation, and the presence of weight loss 113. Parasitic diarrhea withCryptosporidium or Cyclospora can have similar features in the immunologically normal host and would need to be distinguished by specific diagnostic testing 50, 99.

Several methods exist for detection of the parasite. Demonstration of trophozoites or cysts in the stool, called the ova and parasite (O&P) examination, is the traditional means of diagnosis 167. One stool sample will allow the detection of 60 to 80% of infections, 2 stool samples will allow the detection of 80 to 90%, and three stool samples will allow the detection of over 90% 97, 111. However, in some instances, because of intermittent or low levels of shedding, it is necessary to examine more than three stool samples. The desire for more sensitive and specific, as well as faster and reproducible, diagnostic testing has led to the development of immunoassays. Fecal antigen detection using enzyme-linked immunosorbent assays, nonenzymatic immunoassays, or fluorescein-tagged monoclonal antibodies can be superior diagnostic methods to the O&P examination7, 89, 90, 161, 262. It is particularly helpful in assessing cure or in screening for Giardia infection. However, when other parasites are in the differential diagnosis, a stool sample for O&P examination should still be ordered. In the unusual patient for whom a diagnosis cannot be made by O&P examination of stool, endoscopy with duodenal fluid sampling and biopsy may be performed 82, 113, 185, 256. An instance in which this may be helpful is the human immunodeficiency virus-infected patient with diarrhea, whose illness has multiple potential etiologies. Culture and sensitivity testing is available only in research settings 120, 138. DNA probes have been generally limited to detection of parasites in water samples 134, 158, and serologic testing is most useful in epidemiologic surveys 118, 119, 170. Figure 2 outlines an approach to the diagnosis and management of suspected cases of giardiasis and is discussed further below (see “Recommendations”).

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Outline of the diagnosis and management of suspected cases of giardiasis.

THERAPY OF GIARDIASIS

When evaluating the clinical efficacy of agents used againstGiardia, it is difficult to compare studies. They vary as to entry methodology (whether randomization was done and if treatment was blinded or open), population studied (children, adults, symptomatic and/or asymptomatic patients), outcome measures (clinical efficacy and/or stool negativity), and duration of follow-up. Nevertheless, conclusions may be drawn from the studies when viewed as a whole, and statements can be made about the relative efficacy of the agents.

Classes of Agents and Clinical Properties

Nitroimidazoles.The nitroimidazoles class of agents used to treat G. lamblia infection includes metronidazole, tinidazole, ornidazole, and secnidazole. This class was discovered in 1955 and was found to be highly effective against several protozoan infections 240. Metronidazole [1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole; Flagyl] was determined to be therapeutic against Trichomonas vaginalisand Entamoeba histolytica following its discovery in the late 1950s 67, and in 1962 Darbon et al. reported that it could be used to treat giardiasis 57. Since this discovery, metronidazole and other nitroimidazoles have been used by clinicians as the mainstay of therapy of giardiasis.

Of the nitroimidazoles, the mechanism of killing of Giardiaby metronidazole has been the most thoroughly studied. Metronidazole utilizes the anaerobic metabolic pathways present inGiardia. The drug enters the trophozoite, and once it is within the cell, electron transport protein ferredoxins from the parasite donate electrons to the nitro group of the drug 223, 238, 244. The drug becomes “activated” by reduction of this nitro group 223, 238, 240, and a gradient favoring the intracellular transport of metronidazole is established by this reduction reaction. Reduced metronidazole serves as a terminal electron acceptor which binds covalently to DNA macromolecules 72, 177. This results in DNA damage in the form of loss of helical structure, impaired template function, and strand breakage, with subsequent trophozoite death 95. In addition to this effect, metronidazole inhibits trophozoite respiration 81, 189. The reductive activation of metronidazole may also lead to toxic radicals, which react with essential cellular components244. Trophozoites within cysts may be less affected by nitroimidazoles, possibly because of poor penetration of drug through the cyst wall 236. Resistance to metronidazole has been induced in vitro 29. It correlates with decreased activity of parasite pyruvate:ferredoxin oxidoreductase, which is required for reductive activation of nitroimidazoles 239, 247.

Metronidazole is quickly and completely absorbed after oral administration and penetrates body tissues and secretions such as saliva, breast milk, semen, and vaginal secretions 240. The drug is metabolized mainly in the liver and is excreted in the urine 147.

In vitro assays for nitroimidazole drug susceptibility have been performed with G. lamblia since 1980112. Using microscopic evaluation of parasite morphology and mobility, Jokipii and Jokipii first demonstrated that metronidazole and tinidazole were effective 129. Subsequently, morphology 13, 166, 175, growth inhibition 56, 69, 94, 116, 160, 225, [3H]thymidine incorporation32, 117, 164, serum killing 114, vital-dye exclusion 114, 235, inhibition of adherence 21, 55, 79, 166, 192, metabolic 228, and colorimetric133 assays have been employed to measure the in vitro response of the drug to many therapeutic agents. However, as indicated by the variety of assays used, there is no standard for in vitro testing, making it difficult to compare results and apply in vitro findings to the clinical setting.

Of the nitroimidazoles, tinidazole and metronidazole have consistently demonstrated the greatest in vitro activity; tinidazole possesses a slight advantage 30, 32, 55, 101. More highly substituted nitroimidazoles, such as miconazole, clotrimazole, itraconazole, and ketoconazole, were developed for their antifungal activity and are not effective agents against G. lamblia55. Sensitivity to nitroimidazoles can vary depending on the stocks and clones of G. lamblia used in testing 29, 31, 79, 160.

In the United States, metronidazole is the only member of the nitroimidazole class available to treat giardiasis; it is also the most common drug used for treatment worldwide. In spite of its widespread and accepted use against Giardia, the U.S. Food and Drug Administration has never approved it for this indication. Clinical trials have employed dosing two and three times daily (usually 250 mg/dose) for 5 to 10 days and short-course (1 to 3 days), daily single-dose therapy (2.0 or 2.4 g/dose) 261. In the 5- to 10-day schedules the efficacy ranges from 60 to 100% in adult and pediatric patients, with a median efficacy in both groups of 92% (Table 1) 20, 49, 68, 91, 92, 100, 127, 132, 135, 150, 151, 191, 201, 202, 232, 256. In general, this schedule is well tolerated, with most side effects involving gastrointestinal upset and metallic taste (Table2).

View this table:
  • View inline
  • View popup
Table 1.

Efficacy of anti-Giardia drugs in adult and pediatric infectiona

View this table:
  • View inline
  • View popup
Table 2.

Recommended dosing and adverse effects of anti-Giardia drugs

The single-dose, short-course treatments (one high dose given daily) were designed to improve compliance without sacrificing efficacy. They have been used in both adults and children. These regimens are generally less efficacious, particularly if only one dose of metronidazole is given. The efficacy of single-dose therapy ranges from 36 to 60% if the drug is given for 1 day 16, 93, 127, 130, 220, 229 and rises to 67 to 80% if the drug is given for 2 days (Table 1) 127, 130, 146; E. Green, D. M. Lynch, J. A. McFadzean, and I. M. Pugh, Letter, Br. Med. J.2:411–412, 1974). Continuing single-dose treatment for 3 days increases efficacy to the range seen with lower-dose, longer-course therapies 229; Green et al., Letter). The high-dose regimens may also carry more side effects 127.

Children have been included in many of the trials of both long- and short-course therapy, with outcomes similar to those in adults and 80 to 100% efficacy (median, 94%) in the 5- to 10-day regimens 91, 100, 132, 135, 186, 201, 232; A. Rastegar-Lari and A. Salek-Moghaddam, Letter, J. Trop. Pediatr. 42:184–185, 1996). Although metronidazole does not come in a standard liquid form, a suspension can be prepared by thoroughly crushing metronidazole tablets, using a drop of glycerin as a lubricant, and suspending the mixture in Cherry Syrup NF 150.

The most common side effects of metronidazole treatment include headache, vertigo, nausea, and a metallic taste in the mouth (Table 2). Nausea occurs in 5 to 15% of patients given standard multiday courses135, 151. In addition, pancreatitis, central nervous system toxicity at high doses 144, 212, and transient, reversible neutropenia have been attributed to metronidazole147. Patients should be warned to avoid alcohol while taking metronidazole. The inhibition of aldehyde dehydrogenase by metronidazole can cause severe vomiting, flushing, headache, and gastrointestinal pain following alcohol ingestion.

Metronidazole is mutagenic in bacteria and carcinogenic in mice and rats at high doses over long periods 34, 153, 240, 251. However, mutagenicity has never been documented in humans, suggesting that the use of metronidazole is safe in this regard 23, 78, 98, 212. This may, however, mitigate against the short-course high-dose regimens in children.

The finding of therapeutic efficacy with metronidazole spurred investigators to develop and test other nitroimidazole derivatives. The other agents, tinidazole, ornidazole, and secnidazole, each have longer half-lives, making them suitable for single daily-dose therapies217. One dose of tinidazole (Fasigyn) was successfully used in 1971 in a group of Swedish students who acquired giardiasis during a visit to Russia 11. This single, 2-g dose (or equivalent in children) has consistently proven to have a clinical efficacy of 80 to 100% with a median efficacy of 92% (Table 1)16, 126, 130, 131, 146, 151, 193, 222, 229, 261; Z. Farid, N. A. El Masry, W. F. Miner, and A. Hassan, Letter, Lancet ii:721, 1974; T. Pettersson, Letter, Br. Med. J.1:395, 1975) and is far superior to metronidazole when single-dose regimens are directly compared 93, 130, 229, 261. There is also improved compliance with this dosing schedule. The recommended dosing for pediatric populations is usually 50 mg/kg for a single dose (Table 2) 82, 193, 232, 256, and the drug is available in a liquid suspension.

Adverse effects reported with tinidazole are not as common as with metronidazole but do include bitter taste, vertigo, and gastrointestinal upset (Table 2) 130, 131; Pettersson, Letter). Tinidazole is not available in the United States, but travel health providers recommend that some travelers, particularly long-term travelers or overland trekkers in Asia, purchase the drug upon arrival at their country of destination and take it in the event of acquiring giardiasis 113.

Another nitroimidazole derivative which is also not available in the United States is ornidazole. There have been fewer studies with ornidazole, but it has excellent efficacy when given over several days and efficacy similar to tinidazole (92 to 100%) when given as a single dose 19, 131, 145, 220, 232, 261. Single-dose ornidazole (40 mg/kg) has also been given to children, with obvious benefits regarding compliance and cost 39, 186. In one study the drug was given intravenously and was associated with increased side effects, making the investigators reluctant to recommend routine use of this drug in children until large-scale studies of recurrence, carcinogenicity and side effects are completed 39.

Secnidazole, a long-acting 5-nitroimidazole derivative, has been used but is not available in the United States. Similar to tinidazole and ornidazole, secnidazole is usually given as a single dose. The most common regimen is 2 g in adults and 30 mg/kg in children95. Clinical studies demonstrate efficacy rates of over 85% with the single dose in adults 49; R. Baqai, H. Qureshi, and S. J. Zuberi; Letter, J. Pak. Med. Assoc. 45:288, 1995), and in children, this dosing is as effective as a 7- to 10-day course of metronidazole 100; Rastegar-Lari and Salek-Moghaddam, Letter). The drug is rapidly and completely absorbed, has a half-life of 17 to 29 hours, and is metabolized via oxidation in the liver 95. Adverse effects have been reported, most notably gastrointestinal disturbance (nausea, anorexia, and abdominal pain) and dizziness, but usually do not require discontinuation of the drug.

Quinacrine.Quinacrine (Atabrine) was first introduced as an antimalarial agent in 1930, following the work of Kikuth, and became the antimalarial of choice for allied troops in World War II because of its greater availability and better tolerance compared with quinine 240. After the war, it soon became an important agent against G. lamblia, with a clinical efficacy of 90% or more 20, 52, 105, 255. However, with a U.S. market limited to the treatment of Giardia, the use of quinacrine declined, and its production in the United States was discontinued in 1992, although it may still be obtained through alternative sources (Table 2).

The antiprotozoal mechanism of quinacrine is not fully elucidated. The drug intercalates readily with G. lamblia DNA, and it is this interaction which is thought to cause an inhibition of nucleic acid synthesis 240. The differing relative quinacrine uptake rate between human and G. lamblia cells may be responsible for the selective toxicity of the drug 236. In vitro, quinacrine reduces cyst viability and excystation rates179, 189. Resistance has been induced in vitro, and in one study it was correlated with decreased uptake of the drug246. Quinacrine is rapidly absorbed from the intestinal tract and is widely distributed in body tissues.

Although results differ, depending on the in vitro sensitivity testing assay used, metronidazole and furazolidone have been shown to be slightly more potent than quinacrine 30, 32, 55, 94. However, in other studies the in vitro efficacies of quinacrine and metronidazole are the same 21, 117, 164. Some of this difference may be related to the greater variation in sensitivity to quinacrine than to metronidazole or furazolidone between clones ofGiardia31.

Clinically, quinacrine is very effective, with studies establishing its efficacy over 5 to 10 days at about 95% (Table 1) 20, 135, 220, 255. Some researchers consider the drug to be the most efficacious of any of the anti-Giardia therapeutics256. Dosing is usually 100 mg three times a day over 5 to 7 days for adults and 6 mg/kg/day in three divided doses over 5 to 7 days for children (Table 2) 150.

Side effects have precluded many clinicians from using quinacrine, particularly in children (Table 2). A bitter taste, along with vomiting, has been reported in up to 28% of study participants20, 52, and led to a lower efficacy in children younger than 5 years 52, probably due to low compliance. Yellow/orange discoloration of the skin, sclerae, and urine affects 4 to 5% of those taking quinacrine, beginning about 1 week after starting treatment, and can last up to 4 months after discontinuation of therapy. Other common side effects include nausea, vomiting, headache, and dizziness 254. Drug-induced psychosis is uncommon, and exfoliative dermatitis and quinacrine-induced retinopathy are rare 82. Quinacrine can exacerbate psoriasis, and in glucose-6-phosphate dehydrogenase (G6PDH)-deficient individuals, it can precipitate hemolysis. It is contraindicated in pregnancy due to a possible link with spina bifida and renal agenesis. It has never been demonstrated to be carcinogenic, even though it has a mechanism of action of binding to DNA.

Furazolidone.Furazolidone (Furoxone) is one of the thousands of nitrofuran compounds created since the class was discovered in the 1940s 143. It is effective against many bacteria including Klebsiella spp., Clostridiumspp., Escherichia coli, Campylobacter spp., andStaphylococcus aureus. As early as the 1950s, furazolidone was being used in the treatment of giardiasis 253. It is approved for use in the United States and remains an important therapeutic agent worldwide. Of the common anti-Giardiatherapeutics, it is the only one available in a liquid suspension in the United States; therefore, its use has been advocated in pediatric populations 150.

The mechanism of action of furazolidone against G. lamblia, like many of the antiparasitics, is not completely explained. The drug undergoes reductive activation in the G. lambliatrophozoite, but, unlike metronidazole, reduction possibly occurs via an NADH oxidase 38, 244. Its killing effect correlates with the toxicity of reduced products, which can damage important cellular components including DNA. Resistance to furazolidone may be correlated with decreased entry of drug 246 or with increased levels of thiol-cycling enzymes, which can defend against toxic radicals 249. The drug is readily absorbed via the gastrointestinal tract and is metabolized rapidly in tissues, leading to low concentrations in serum and urine 143.

In in vitro susceptibility testing, furazolidone performs comparably to metronidazole and has consistently demonstrated the highest activity of the nonimidazoles 32, 55, 101; it is more active than quinacrine 30.

Clinical studies using furazolidone are numerous and have been completed with a wide range of subjects, doses, and administration schedules. Although its efficacy has generally been considered to be slightly lower than those of metronidazole and quinacrine, curative rates between 80 and 96% have been reported for 7- to 10-day courses (Table 1) 20, 52, 91, 151, 178, 191, 201, 255. It is when the drug is given for only 5 days that efficacy falls off considerably151, 178. It is given as four doses per day in both adults (100 mg per dose) and children (1.5 mg/kg) (Table 2). In the pediatric suspension, two tablespoonfuls substitute for a 100-mg tablet.

About 10% of patients report gastrointestinal symptoms such as nausea, vomiting, and diarrhea (Table 2) 150, 256. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors. There have been rare reports of disulfiram-like reactions when it is taken with alcohol164b. A furazolidone-induced manic episode in a patient infected with human immunodeficiency virus has been reported73. Furazolidone is also contraindicated in infants younger than 1 month of age, who could develop hemolytic anemia because of their normally unstable glutathione. Finally, the drug is mutagenic in bacteria and has been demonstrated to cause mammary tumors in rats and pulmonary tumors in mice when given in chronic high doses. However, the implication of this finding for humans is not known and has not been adequately addressed 143, 164b, 236. When treating pediatric populations, the advantages of its minimal adverse effects and the availability of a liquid suspension must be weighed against the need for frequent dosing over a 10-day treatment period.

Benzimidazoles.Two members of the benzimidazole class of therapeutics, albendazole (Albenza) and mebendazole (Vermox), have been used to treat G. lamblia infection 155. Clinical and in vitro efficacy studies have produced different results as to their effectiveness. However, a comparatively benign side effect profile, combined with proven efficacy against many helminths, renders them promising for treatment 208, 250.

The benzimidazoles exert their toxic effect on Giardia in part by binding to the G. lamblia β-tubulin cytoskeleton71, 175, 209. This binding causes both inhibition of cytoskeleton polymerization and impaired glucose uptake250. Although the exact binding site on the cytoskeleton has not been determined, it is postulated that a benzimidazole-colchicine site interaction may play a role 51, 166, 236. The benzimidazoles are poorly absorbed from the gastrointestinal tract, although this can be improved with the coingestion of a fatty meal. The systemic effect of albendazole is due to its primary metabolite, albendazole sulfoxide, which is rapidly formed in the liver following absorption 3. Excretion by the kidneys is negligible.

In vitro susceptibility testing of G. lamblia to the benzimidazoles is limited in comparison to the susceptibility of the parasite to the nitroimidazoles or quinacrine. Nevertheless, studies demonstrate a considerable in vitro effect 79, 175, 208, 209. One report showed that both albendazole and mebendazole were 30- to 50-fold more active than metronidazole and 4- to 40-fold more active than quinacrine in vitro 71. Another demonstrated that the ability of albendazole to affect trophozoite morphology, adherence, and viability was far greater than that of metronidazole or tinidazole 166. However, their variable clinical efficacy demonstrates the discordance between in vitro testing and in vivo activity. Resistance to albendazole can be induced in vitro154 and correlates with changes in the parasite cytoskeleton 243. Other benzimidazoles such as nocodazole, oxfendazole, thiabendazole, and fenbendazole have also demonstrated some in vitro efficacy 236.

Clinical trials have been limited to albendazole and mebendazole, with mixed results. Hall and Nahar reported equal curative efficacy of albendazole and metronidazole in children when albendazole was given for 5 days but not when it was given in single or 3-day dosing (Table1) 104. A decreased efficacy of albendazole when given for 3 days or less was also documented by Kollaritsch et al. in travelers with giardiasis 137, by Pungpak et al. in children and adults 198, and by Pengsaa et al. in children193. Improved efficacy was seen in other patients when the drug was given for 5 days 171, 207, 214 or 7 days198. The exception to the need for longer treatment courses was seen in one study in which a single dose was administered68. An albendazole-metronidazole combination was 100% effective in 20 patients with metronidazole-resistant giardiasis who had failed three to five courses of standard oral metronidazole therapy44.

Treatment with mebendazole has resulted in widely divergent clinical results. Al-Waili reported over 90% efficacy in two studies in children 8, 9. However, other studies in both pediatric and adult populations have not shown equal success but instead have shown effectiveness in 80% 211 and in 60% or less39, 92, 132; L. di Martino, A. Nocerino, and M. Pettoello Mantovani, Letter, Trans. R. Soc. Trop. Med. Hyg.85:557–558, 1991), as well as a failure to decrease the prevalence rates of Giardia when mebendazole was used in mass treatment of helminths 219. Because of this discrepancy, most interest has focused on albendazole.

The dosage in adults is usually 400 mg per day for 5 days for albendazole and 200 to 400 mg per day for 5 to 10 days for mebendazole (Table 2). The usual dosage in children is 15 mg/kg per day for 5 to 7 days. Both drugs are available in suspension. One advantage of using albendazole in children is its efficacy against many helminths, allowing effective treatment of multiple intestinal parasites207, 208. Another advantage is its relative lack of side effects. However, with short-term use, it may cause gastrointestinal problems of anorexia and constipation. Long-term, high-dose use of albendazole, such as when it is used for larval cestode infections, has caused reversible neutropenia and elevated hepatic enzyme levels3, 155, 258. Albendazole is contraindicated in pregnancy, due to possible teratogenicity (pregnancy category C), but animal studies have shown no increase in carcinogenic incidence.

Paromomycin.Paromomycin (Humatin), a member of the aminoglycoside family, was first isolated in 1956. It is indicated for the treatment of Entamoeba histolytica andTrichomonas and has been proposed as a treatment forG. lamblia in resistant infections and during pregnancy113, 140. Paromomycin is poorly absorbed from the intestinal lumen; even large-dose oral administrations achieve only minimal concentrations in the blood and urine of patients with normal renal function 140. Paromomycin inhibits G. lamblia protein synthesis by interfering with the 50S and 30S ribosomal subunits (the parasite rRNA has an unusual size and sequence) and causing misreading of mRNA codons 69.

In vitro susceptibility testing demonstrates that paromomycin has activity against G. lamblia, but the activity is generally lower than that of the nitroimidazoles, quinacrine, or furazolidone30, 101. However, because of poor intestinal absorption, it compensates for its low antiprotozoal activity by achieving high levels in the gut. In a rat model, the drug showed efficacy15.

Clinical studies are limited, and therapeutic efficacy ranges from 55 to nearly 90% (Table 1) 47, 63, 140, 191, 218. The usual dose is 500 mg three times per day for 10 days in adults and 25 to 30 mg/kg/day (divided into three doses) in children (Table 2).

As with other aminoglycosides, if absorbed systemically paromomycin can cause ototoxicity and nephrotoxicity. However, it may be less ototoxic than other aminoglycosides 142, and with limited systemic absorption, toxicity should not be a concern in persons with normal kidneys. However, it should be used with caution in those with impaired renal function.

Bacitracin zinc.The search for alternative, effective anti-Giardia therapeutics has led investigators to consider bacitracin. Bacitracin was first isolated in 1945 from a strain ofBacillus and was used systemically against severe staphylococcal infections until 1960, when its toxicity and the availability of other antibiotics restricted it to mainly topical use141. Zinc was added to the bacitracin complex to promote stability. Bacitracin exerts its effect in bacteria by interfering with a dephosphorylation step in cell membrane synthesis. Following demonstrated in vitro effectiveness against E. histolyticaand Trichomonas, bacitracin zinc was tested againstGiardia in vitro and found to be active 12, 13.

A clinical trial by Andrews et al. used twice-daily dosing over 10 days and compared the effectiveness of 120,000 U of bacitracin zinc, 120,000 U of bacitracin, 120,000 U of neomycin, and 60,000 U of bacitracin zinc in combination with 60,000 U of neomycin 14. Cure rates of 95% for bacitracin zinc, 88% for either bacitracin or the bacitracin zinc-neomycin combination, and 86% for neomycin were demonstrated. Adverse effects were limited to a small number of patients who experienced diarrhea, abdominal discomfort, constipation, and nausea. Children younger than 10 years were excluded from the study.

The disadvantages of using bacitracin zinc include a potential for nephrotoxicity with prolonged oral dosing and gastrointestinal disturbance. Furthermore, compliance can be affected by the 10-day dosing period, and the formulations used by Andrews in their study are not readily available. Although bacitracin zinc is promising, more investigation is needed before it can gain wide acceptance as an agent against G. lamblia.

Emerging and experimental therapeutics.A wide variety of chemotherapeutic agents including rifampin, bithionol, dichlorophene, hexachlorophene, pyrimethamine, sodium fusidate, chloroquine, and mefloquine have demonstrated in vitro activity againstGiardia81, 84, 233. Lipophilic tetracyclines, such as doxycycline, are highly active in vitro; however, their clinical efficacy is limited, perhaps because of their rapid absorption from the intestine 70. Certain pentamidine analogs, as well as azithromycin, have in vitro activity comparable to that of metronidazole 25, 33.

Nitazoxanide, a 5-nitrothiazole derivative with broad-spectrum activity against protozoa, helminths, and some bacteria has shown limited efficacy in adults and children in Mexico (71% [213] and 78% [211] effectiveness, respectively) and in a few AIDS patients in Mali64. It has been given in a dose of 100 to 500 mg twice daily for 3 to 7 days.

Studies using a rat model have demonstrated the efficacy of ivermectin under specific conditions 260. Disulfiram, a zinc finger-active compound used for the treatment of alcoholism in humans, shows significant cure rates and decreased parasitic burdens in a mouse model of giardiasis 180.

In an ethnobotanical survey of the anti-Giardiagastrointestinal remedies employed by the Luo tribes of East Africa, methanolic extracts of 21 of the 36 taxa studied were lethal to or inhibited the growth of G. lamblia in vitro124. Geranium nivem extracts have also shown in vitro activity 45. The immunomodulatory herbal drugPippali rasayana, often prescribed for the treatment of worm infections and chronic dysentery in India, achieved a 98% cure of murine infection with G. lamblia6. Extracts ofPiper longum fruit were effective in a mouse model of infection 241.

Proposlina, a bee glue preparation, demonstrated a 60% parasitologic cure rate 1 week after treatment was completed among 48 adults in Cuba172, 261. In a patient with metronidazole-resistantGiardia infection, the β-adrenergic antagonistdl-propranolol, given in a dose of 40 mg three times a day with 400 mg of metronidazole three times a day for 10 days, cleared infection, demonstrating clinical efficacy in humans 197. In vitro studies demonstrate that propranolol exerts its effect by inhibiting the motility and growth of the protozoan, most probably due to the membrane-stabilizing activity of the drug 85. However, further studies with dl-propranolol and the related compound d-propranolol are needed before they can be recommended as anti-Giardia agents.

Immunoprophylactic strategies to prevent or treat giardiasis have generally not been effective 87. Passive transfer of anti-Giardia immune serum did not facilitate parasite clearance in murine giardiasis 76, 242. Although patients with common variable immunodeficiency do have symptomatic and prolonged infection with Giardia antiparasitic therapy is required to control their infection 106, 216. Breast milk can be cytotoxic to Giardia via free fatty acids which are generated from milk triglycerides by the action of a bile salt-stimulated lipase 204. Also, breast feeding may confer some protection to suckling infants 176, 183; however the approach of providing enteral anti-Giardiaantibody has not been studied.

Special Situations

Pregnancy and lactation.The management of symptomaticG. lamblia infection during pregnancy is a challenge for the clinician because no therapeutic agent combines optimal efficacy and safety. Women who are asymptomatic, have mild disease, or are in their first trimester should usually avoid being treated. However, women in whom adequate hydration and nutritional status cannot be maintained should be treated, even in the first trimester.

Metronidazole, which rapidly enters the fetal circulation after absorption by the mother, has demonstrated mutagenicity in bacteria and carcinogenicity in mice and rats 34, 36, 153, 240, 251. While this information raises concern about the use of the drug during pregnancy, carcinogenicity has not been demonstration in humans23, 24, 78, 98, 212, nor has there been teratogenicity in rodents 164a. Metronidazole has been used extensively during pregnancy (pregnancy category B), primarily for therapy of trichomoniasis in 7- to 10-day courses 42. The results regarding safety to the fetus are conflicting 36, 42, 107, 212, 215, 218. One retrospective study of 1,469 women who took metronidazole in pregnancy, with 206 using the drug in the first trimester, found no evidence of congenital abnormality 26. However, the Collaborative Perinatal Project, including over 50,000 mother-child pairs, demonstrated that first-trimester exposure to metronidazole in 31 women showed a possible association with malformations 107. A meta-analysis of seven studies, prospectively monitoring 253 mother-infant pairs and retrospectively monitoring 1,083 pairs, found no increased risk of fetal malformation in association with first-trimester use of metronidazole42, with one report estimating a relative risk of 0.92 for birth defects 215. On balance, there may be a slightly increased risk when using metronidazole during the first trimester, and thus its use should be avoided during this period. High-dose (≥2.0 g), short-course regimens should not be given during pregnancy.

Metronidazole is actively excreted in breast milk in concentrations similar to those in plasma. The American Academy of Pediatrics (AAP) recommends giving a single 2-g dose in nursing mothers, followed by discontinuation of nursing for 12 to 24 h 10, 36. The AAP also recommends that mothers taking tinidazole discontinue nursing for the same time period as those taking metronidazole 10. However, metronidazole is approved for use in children for therapy of amebiasis and is used in children for therapy of anaerobic infections, so it would seem that the small amount secreted in breast milk would not be deleterious. Also, since single, high-dose regimens of metronidazole have poor efficacy and would be expected to lead to higher levels in breast milk, these findings favor traditional treatment with lower doses over 5 to 7 days.

Paromomycin is generally considered safe because it is poorly absorbed from the intestine and excreted almost 100% unchanged in the feces. Therefore, little if any of the drug will reach the fetus. However, it is not as effective as metronidazole or quinacrine. In addition, no clinical trials have addressed the effects of high serum concentrations of paromomycin during pregnancy. Nevertheless, paromomycin has been used successfully to eradicate G. lamblia infection in the gravid patient and is an important agent to consider during the first trimester, when metronidazole should not be used 140, 218. Paromomycin should also be safe in nursing mothers. A study in ewes showed only a 0.018% drug recovery rate in breast milk for the 12 h following parenteral administration 36, 263. The AAP does designate streptomycin and kanamycin, aminoglycoside relatives of paromomycin, to be compatible with breast feeding 10.

One expert on giardiasis has espoused quinacrine treatment in pregnant patients due to its high cure rate 256. While the drug is very effective, its slow excretion from the body and proven teratogenicity in rats make it a suboptimal choice for treatment in pregnancy. Although quinidine and quinine are compatible with breast-feeding, no information regarding the safety of quinacrine for the breast-fed child was available 10.

Furazolidone is not recommended for the pregnant patient. Although it is efficacious, its has caused mammary tumors in mice and mutations in bacteria, which should deter the physician from using it in this setting 164b. Its safety for breast-fed children is not known. Albendazole is considered a pregnancy category C agent, and has been teratogenic in rats and rabbits, although there is little experience of its effects in pregnant women.

Asymptomatic infection.On a global basis, most persons infected with G. lamblia are asymptomatic or minimally symptomatic. Treating asymptomatic patients, particularly children, is controversial, and there are several factors to consider before initiating therapy. The setting of the infection plays a key role in the decision. In areas where G. lamblia is endemic, treatment may not be desirable because the children are likely to become rapidly reinfected following treatment 96, 231. IfGiardia contributes to failure of growth and development86, 163, 227, treatment, even though reinfection may occur, might allow catch-up growth 103 and might be worth the cost and effort. A drug such as albendazole, which would also treat nematode infections, might be useful in these settings; however, the requirement for 5-day dosing would make it difficult to complete therapy in many situations.

In conditions in which the child's nutritional baseline is excellent, such as in day care centers in the developed world, asymptomatic carriers may not always need therapy 5, 121, 195, 203, 221, 237. However, it should be noted, that aymptomatically infected children may excrete Giardia for months 195, carry it home to family members and thus initiate infection in the household, and even help maintain high levels of Giardiainfection in a community 4, 196, 224; G. D. Overturf, Editorial, Clin. Infect. Dis. 18:764–765, 1994). It is not uncommon for a mother of a young child in day care to become symptomatic with giardiasis, identifying the presence in the household of Giardia which has been introduced by the asymptomatic child. If there is recurrent diarrhea attributed to Giardiain day care which cannot be controlled by improved hygiene and by treatment and exclusion of children who are symptomatic, consideration can be given to screening and treating all the children in the day care setting 5, 18, 230.

If Giardia is detected in the stool and there is little likelihood of reinfection, such as in a returned traveler, treatment can be given. In the household, if one member is symptomatic and there is the possibility that fecal-oral spread has occurred within the family or that there is a common source of infection, all family members should be screened and treated so that reinfection will not occur.

Another factor to consider in deciding whether to treat asymptomatic carriers is the consequences of transmission of infection if the carrier is not treated, e.g., infection in food handlers 169, 199. This group should be treated to prevent food-borne outbreaks.

Resistance and relapse.Treatment failures have been reported with all of the common anti-Giardia agents including metronidazole, quinacrine, furazolidone, and albendazole. However, it is important for the clinician faced with recurrence of symptoms after therapy to differentiate between actual drug resistance, cure followed by reinfection, and post-Giardia lactose intolerance. Therefore, the first step is to document true, persistent infection by sending a stool sample for O&P examination orGiardia antigen detection. If the sample is positive, a careful exposure history should provide information about the likelihood of reinfection, and reinfected individuals should respond to the original therapeutic agent. Reinfection would be common in regions of endemicity around the world and in situations of poor fecal-oral hygiene. If a patient has become reinfected, risk factors should be identified and the patient should be counseled regarding proper hygiene and prevention measures.

Post-Giardia lactose intolerance is the most common of the disaccharidase deficiencies associated with giardiasis and may occur in 20 to 40% of patients 65. Thus, if the stool is negative for Giardia, a trial of avoiding lactose-containing foods and liquids should be instituted. This syndrome may take several weeks to resolve.

True treatment failure could mean infection with a drug-resistant isolate of Giardia. Resistance to most anti-Giardia agents has been documented or induced in vitro29, 154, 245-247, and multiple, genotypically different clones of G. lamblia with different drug class susceptibilities have been found in the human duodenum 46, 81, 160, 248. However, there has not been a consistent correlation between in vitro resistance or sensitivity and clinical failure or success 43, 160, 164, 225, 249, still leaving open the question of true parasite resistance.

Clinically resistant strains have been treated with longer repeat courses or higher doses of the original agent 91, 165, 178. However, the most efficacious means of eradicating these infections seems to involve using a drug from a different class to avoid potential cross-resistance 52, 92. An initial switch to a drug of a different class may not always be effective as demonstrated in two French patients who failed albendazole treatment following two courses of metronidazole but did respond to quinacrine (P. Brasseur and L. Favennec, Letter, Parasite 2:422, 1995). Combination regimens using metronidazole-albendazole, metronidazole-quinacrine, or other active drugs or giving a nitroimidazole plus quinacrine for courses of at least 2 weeks have proven successful against refractory infection 44, 182a, 197, 225, 234. On occasion, several different combinations or approaches will be necessary to effect cure.

In cases of giardiasis in which alternative therapy is not effective, other possibilities should be considered, such as the presence of immunologic deficiency. Chronic giardiasis in patients with hypogammaglobulinemia is well recorded 106, 108, 216 and can be difficult to treat, often requiring prolonged courses of therapy. Although Giardia is seen in homosexual men who engage in oral-anal sexual practices 162, 200, 226, illness may often be neither severe nor prolonged 148. Nevertheless, in AIDS patients with severe giardiasis, prolonged or combination therapy may be necessary 182a.

RECOMMENDATIONS

An approach to the diagnosis and management of suspected giardiasis is illustrated in Fig. 2 and discussed in more detail above (see “Background”). If stools are negative, an empiric course of therapy can be given; however, an alternative diagnosis should be considered. If there is no response to therapy in stool-negative cases, invasive testing by endoscopy can be performed to help determine the diagnosis, particularly if the patient is immunocompromised.

When treatment is carried out, the agents of choice are listed in Table3 and the dosages are given in Table 2. The most effective agents for therapy of giardiasis are single doses of tinidazole or ornidazole, 5 to 7 days of quinacrine, and 5 to 7 days of metronidazole. Tinidazole and ornidazole are not approved or available in the United States. Production of quinacrine has been discontinued, but it still may be obtained on a limited basis; however, it has significant side effects, particularly in children. Therefore, the treatment of choice in the United States for both adults and children is metronidazole. A standard course of 5 to 7 days should effectively treat 90% or more of infected individuals. Although the efficacy of 3 days of 2 to 2.4 g in a single daily dose approaches that of longer regimens, this regimen is not recommended. The drug has not received a Food and Drug Administration indication for giardiasis, and these high doses may have increased side effects. Furazolidone is an effective alternative but requires 7 to 10 days of treatment four times a day, which will probably affect compliance. Of the newer therapeutics, albendazole in a 5-day regimen seems most promising, but additional studies are needed. It has the advantage of having broad antiparasitic effect, which may be beneficial in developing-world settings.

View this table:
  • View inline
  • View popup
Table 3.

Recommendations for therapy of giardiasis

In pregnancy, if treatment is required, paromomycin should be tried in the first trimester and paromomycin or metronidazole should be used in the second and third trimesters.

Treatment of all asymptomatic patients calls for careful interpretation of the clinical situation, but they may not always require therapy.

It can be expected that parasites will be cleared from the stool in 3 to 5 days and that symptoms will resolve in 5 to 7 days 91, 100, 131, 171. If the symptoms do not abate, the patient should be evaluated for treatment failure or lactose intolerance. If resistance or relapse has occurred, treatment with a drug of a different class or with a combination of a nitroimidazole and quinacrine for at least 2 weeks should eradicate infection.

ACKNOWLEDGMENT

We thank Theodore Nash for helpful comments and suggestions.

  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.
    Reference deleted.
  2. 2.
    Reference deleted.
  3. 3.↵
    1. Abdi Y. A.,
    2. Gustafsson L. L.,
    3. Ericsson O.,
    4. Hellgren U.
    Handbook of drugs for tropical parasitic infections 2nd ed. 1995 12 16 Taylor & Francis Ltd. London, United Kingdom
  4. 4.↵
    1. Addiss D. G.,
    2. Davis J. P.,
    3. Roberts J. M.,
    4. Mast E. E.
    Epidemiology of giardiasis in Wisconsin: increasing incidence of reported cases and unexplained seasonal trend. Am. J. Trop. Med. Hyg. 47 1992 13 19
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Addiss D. G.,
    2. Juranek D. D.,
    3. Spencer H. C.
    Treatment of children with asymptomatic and nondiarrheal Giardia infection. Pediatr. Infect. Dis. J. 10 1991 843 846
    OpenUrlPubMed
  6. 6.↵
    1. Agarwal A. K.,
    2. Singh M.,
    3. Gupta M.,
    4. Saxena R.,
    5. Puri A.,
    6. Verma A. K.,
    7. Saxena R. P.,
    8. Dubey C. B.,
    9. Saxena K. C.
    Management of giardiasis by an immuno-modulatory herbal drug Pippali rasayana. J. Ethnopharmacol. 44 1994 143 146
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Aldeen W. E.,
    2. Carroll K.,
    3. Robison A.,
    4. Morrison M.,
    5. Hale D.
    Comparison of nine commercially available enzyme-linked immunosorbent assays for the detection of Giardia lamblia in fecal specimens. J. Clin. Microbiol. 36 1998 1338 1340
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Al-Waili N. S.,
    2. Al-Waili B. H.,
    3. Saloom K. Y.
    Therapeutic use of mebendazole in giardial infections. Trans. R. Soc. Trop. Med. Hyg. 82 1988 438
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Al-Waili N. S. D.,
    2. Hasan N. U.
    Mebendazole in giardial infections: a comparative study with metronidazole. J. Infect. Dis. 165 1992 1170 1171
    OpenUrlPubMedWeb of Science
  10. 10.↵
    American Academy of Pediatrics Committee on Drugs The transfer of drugs and other chemicals into human milk. Pediatrics 93 1994 137 150
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Andersson T.,
    2. Forssell J.,
    3. Sterner G.
    Outbreak of giardiasis: effect of a new antiflagellate drug, tinidazole. Br. Med. J. 2 1972 449 451
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Andrews B. J.,
    2. Bjorvatin B.
    Chemotherapy of Entamoeba histolytica: studies in vitro with bacitracin and its zinc salt. Trans. R. Soc. Trop. Med. Hyg. 88 1994 98 100
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Andrews B. J.,
    2. Mylvaganam H.,
    3. Yule A.
    In vitro sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bacitracin and its zinc salt. Trans. R. Soc. Trop. Med. Hyg. 88 1994 704 706
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Andrews B. J.,
    2. Panitescu D.,
    3. Jipa G. H.,
    4. Vasile-Bugarin A. C.,
    5. Vasiliu R. P.,
    6. Ronnevig J. R.
    Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with neomycin. Am. J. Trop. Med. Hyg. 52 1995 318 321
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Awadalla H. N.,
    2. el-Gowhary S. H.,
    3. Sadaka H. A. H.,
    4. Khalifa A. M.
    Aminosidine sulphate in experimental giardiasis. J. Egypt. Soc. Parasitol. 25 1995 53 61
    OpenUrlPubMed
  16. 16.↵
    1. Bakshi J. S.,
    2. Ghiara J. M.,
    3. Nanivadeker A. S.
    How does tinidazole compare with metronidazole? A summary of reports of Indian trials in amoebiasis and giardiasis. Drugs 15 1978 S31 S42
    OpenUrl
  17. 17.
    Reference deleted.
  18. 18.↵
    1. Bartlett A. V.,
    2. Englender S. J.,
    3. Jarvis B. A.,
    4. Ludwig L.,
    5. Carlson J. F.,
    6. Topping J. P.
    Controlled trial of Giardia lamblia: control strategies in day care centers. Am. J. Public Health 81 1991 1001 1006
    OpenUrlPubMed
  19. 19.↵
    1. Bassily S.,
    2. Farid Z.,
    3. el Masry N. A.,
    4. Mikhail E. M.
    Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole, and ornidazole: a comparative study. J. Trop. Med. Hyg. 90 1987 9 12
    OpenUrlPubMed
  20. 20.↵
    1. Bassily S.,
    2. Farid Z.,
    3. Mikhail J. W.,
    4. Kent D. C.,
    5. Lehman J. S.
    The treatment of Giardia lamblia infection with mepacrine, metronidazole and furazolidone. J. Trop. Med. Hyg. 73 1970 15 18
    OpenUrlPubMedWeb of Science
  21. 21.↵
    1. Baveja U. K.,
    2. Bhatia V. N.,
    3. Warhurst D. C.
    Giardia lamblia: in-vitro sensitivity to some chemotherapeutic agents. J. Commun. Dis. 30 1998 79 84
    OpenUrlPubMed
  22. 22.↵
    1. Bean N. H.,
    2. Goulding J. S.,
    3. Lao C.,
    4. Angulo F. J.
    Surveillance for foodborne-disease outbreaks—United States, 1988–1992. CDC Surveillance Summaries, October 25, 1996. Morb. Mortal. Wkly. Rep. 45 NSS-5 1996 1 66
    OpenUrlPubMed
  23. 23.↵
    1. Beard C. M.,
    2. Noller K. L.,
    3. O'Fallon W. M.
    Cancer after exposure to metronidazole. Mayo Clin. Proc. 63 1988 147 153
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Beard C. M.,
    2. Noller K. L.,
    3. O'Fallon W. M.,
    4. Kurland L. T.,
    5. Dockerty M. B.
    Lack of evidence for cancer due to use of metronidazole. N. Engl. J. Med. 301 1979 519 522
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Bell C. A.,
    2. Cory M.,
    3. Fairley T. A.,
    4. Hall J. E.,
    5. Tidwell R. R.
    Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity. Antimicrob. Agents Chemother. 35 1991 1099 1107
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Berget A.,
    2. Weber T.
    Metronidazole and pregnancy. Ugeskr. Laeg. 134 1972 2085 2089
    OpenUrlPubMed
  27. 27.↵
    1. Bingham A. K.,
    2. Meyer E. A.
    Giardia excystation can be induced in vitro in acidic solutions. Nature (London). 277 1979 301 302
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Black R. E.,
    2. Dykes A. C.,
    3. Sinclair S. P.,
    4. Wells J. G.
    Giardiasis in day-care centers: evidence of person-to-person transmission. Pediatrics 60 1977 486 491
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Boreham P. F. L.,
    2. Phillips R. E.,
    3. Shepherd R. W.
    Altered uptake of metronidazole in vitro by stocks of Giardia intestinalis with different drug sensitivities. Trans. R. Soc. Trop. Med. Hyg. 82 1988 104 106
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Boreham P. F. L.,
    2. Phillips R. E.,
    3. Shepherd R. W.
    A comparison of the in-vitro activity of some 5-nitroimidazoles and other compounds against Giardia intestinalis. J. Antimicrob. Chemother. 16 1985 589 595
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Boreham P. F. L.,
    2. Phillips R. E.,
    3. Shepherd R. W.
    Heterogeneity in the responses of clones to Giardia intestinalis to anti-giardial drugs. Trans. R. Soc. Trop. Med. Hyg. 81 1987 406 407
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Boreham P. F. L.,
    2. Phillips R. E.,
    3. Shepherd R. W.
    The sensitivity of Giardia intestinalis to drugs in vitro. J. Antimicrob. Chemother. 14 1984 449 461
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Boreham P. F. L.,
    2. Upcroft J. A.
    The activity of azithromycin against stocks of Giardia intestinalis in vitro and in vivo. Trans. R. Soc. Trop. Med. Hyg. 85 1991 620 621
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Bost R. G.
    Metronidazole: mammalian mutagenicity Proceedings of the International Metronidazole Conference, Montreal, Canada. 1977 126 131 Excerpta Medica Amsterdam, The Netherlands
  35. 35.
    Reference deleted.
  36. 36.↵
    1. Briggs G. G.,
    2. Freeman R. K.,
    3. Yaffe S. J.
    Metronidazole Drugs in pregnancy and lactation 3rd ed. Briggs G. G., Freeman R. K., Yaffe S. J. 1990 430 433 The Williams & Wilkins Co. Baltimore, Md
  37. 37.↵
    1. Brodsky R. E.,
    2. Spencer H. C.,
    3. Schultz M. G.
    Giardiasis in American travelers to the Soviet Union. J. Infect. Dis. 130 1974 319 323
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Brown D. M.,
    2. Upcroft J. A.,
    3. Upcroft P.
    A H2O-producing NADH oxidase from the protozoan parasite Giardia duodenalis. Eur. J. Biochem. 241 1996 155 161
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Bulut B. U.,
    2. Gulnar S. B.,
    3. Aysev D.
    Alternative treatment protocols in giardiasis: a pilot study. Scand. J. Infect. Dis. 28 1996 493 495
    OpenUrlPubMedWeb of Science
  40. 40.↵
    1. Buret A.,
    2. denHollander N.,
    3. Wallis P. M.,
    4. Befus D.,
    5. Olson M. E.
    Zoonotic potential of giardiasis in domestic ruminants. J. Infect. Dis. 162 1991 231 237
    OpenUrl
  41. 41.↵
    1. Buret A.,
    2. Gall D. G.,
    3. Nation P. N.,
    4. Olson M. E.
    Intestinal protozoa and epithelial kinetics, structure and function. Parasitol. Today 12 1990 375 380
    OpenUrl
  42. 42.↵
    1. Burtin P.,
    2. Taddio A.,
    3. Ariburnu O.,
    4. Einarson T. R.,
    5. Koren G.
    Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol. 172 1995 525 529
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Butcher P. D.,
    2. Cevallos A. M.,
    3. Carnaby S.,
    4. Alstead E. M.,
    5. Swarbrick E. T.,
    6. Farthing M. J. G.
    Phenotypic and genotypic variation in Giardia lamblia isolates during chronic infection. Gut 35 1994 51 54
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Cacopardo B.,
    2. Patamia I.,
    3. Bonaccorso V.,
    4. Di Paola O.,
    5. Bonforte S.,
    6. Brancati G.
    Efficacia sinergica dell'associazione albendazole-metronidazolo nella giardiasi refrattaria a monoterapia con metronidazolo. Clin. Ter. 146 1995 761 767
    OpenUrlPubMed
  45. 45.↵
    1. Calzada F.,
    2. Cerda-Garcia-Rojas C. M.,
    3. Meckes M.,
    4. Cedillo-Rivera R.,
    5. Bye R.,
    6. Mata R.
    Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium nivem. J. Nat. Prod. 62 1999 705 709
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Carnaby S.,
    2. Ketelaris P. H.,
    3. Neem A.,
    4. Farthing M. J. G.
    Genotypic heterogeneity within Giardia lamblia isolates demonstrated by M13 DNA fingerprinting. Infect. Immun. 62 1994 1875 1880
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Carter C. H.,
    2. Bayles A.,
    3. Thompson P. E.
    Effects of paromomycin sulfate in man against Entamoeba histolytica and other intestinal protozoa. Am. J. Trop. Med. Hyg. 11 1962 448 451
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Chávez B.,
    2. González-Mariscal L.,
    3. Cedillo-Rivera R.,
    4. Martı́nez-Palomo A.
    Giardia lamblia: in vitro cytopathic effect of human isolates. Exp. Parasitol. 80 1995 133 138
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Cimerman B.,
    2. Boruchovski H.,
    3. Cury F. M.,
    4. Bichued L. M.,
    5. Ieri A.
    A comparative study of secnidazole and metronidazole in the treatment of giardiasis Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy. Katz N., Willis A. T. 1989 28 34 Excerpta Medica Amsterdam, The Netherlands
  50. 50.↵
    1. Clark D. P.
    New insights into human cryptosporidiosis. Clin. Microbiol. Rev. 12 1999 554 563
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Clark J. T.,
    2. Holberton D. V.
    Triton-labile antigens in flagella isolated from Giardia lamblia. Parasitol. Res. 74 1988 415 423
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Craft J. C.,
    2. Murphy T.,
    3. Nelson J. D.
    Furazolidone and quinacrine. Comparative study of therapy for giardiasis in children. Am. J. Dis. Child. 135 1981 164 166
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Craun G. F.
    Waterborne giardiasis in the United States 1965–1984. Lancet ii 1986 513 514
    OpenUrl
  54. 54.↵
    1. Craun G. F.
    Waterborne outbreaks of giardiasis: current status Giardia and giardiasis: biology, pathogenesis, and epidemiology. Erlandsen S. L., Meyer E. A. 1996 243 261 Plenum Press New York, N.Y
  55. 55.↵
    1. Crouch A. A.,
    2. Seow W. K.,
    3. Thong Y. H.
    Effect of twenty-three chemotherapeutic agents on the adherence and growth of Giardia lamblia in vitro. Trans. R. Soc. Trop. Med. Hyg. 80 1986 893 896
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Crouch A. A.,
    2. Seow W. K.,
    3. Whitman L. M.,
    4. Thong Y. H.
    Sensitivity in vitro of Giardia intestinalis to dyadic combinations of azithromycin, doxycycline, mefloquine, tinidazole and furazolidone. Trans. R. Soc. Trop. Med. Hyg. 84 1990 246 248
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Darbon A.,
    2. Portal A.,
    3. Girier L.,
    4. Pantin J.,
    5. Leclaire C.
    Traitement de la giardiase (lambliase) par le métronidazole. Presse Med. 70 1962 15 16
    OpenUrlPubMed
  58. 58.↵
    1. Davidson R. A.
    Issues in clinical parasitology: the treatment of giardiasis. Am. J. Gastroenterol. 79 1984 256 261
    OpenUrlPubMed
  59. 59.↵
    1. deRegnier D. P.,
    2. Cole L.,
    3. Schupp D. G.,
    4. Erlandsen S. L.
    Viability of Giardia cysts suspended in lake, river, and tap water. Appl. Environ. Microbiol. 55 1989 1223 1229
    OpenUrlAbstract/FREE Full Text
  60. 60.
    Reference deleted.
  61. 61.↵
    1. Djamiatun K.,
    2. Faubert G. M.
    Exogenous cytokines released by spleen and Peyer's patch cells removed from mice infected with Giardia muris. Parasite Immunol. 20 1998 27 36
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Dobell C.
    The discovery of the intestinal protozoa of man. Proc. R. Soc. Med. 13 1920 1 15
    OpenUrl
  63. 63.↵
    1. Dobón J. F.,
    2. Cedrato A. E.,
    3. Martino de Colom N.
    El uso de la paromomicina en amebiasis y giardiasis intestinalis 11 July 1963 1012 El Dı́a Médico Buenos Aires, Argentina
  64. 64.↵
    1. Doumbo O.,
    2. Rossignol J. F.,
    3. Pichard E.,
    4. Traore H. A.,
    5. Dembele M.,
    6. Diakite M.,
    7. Traore F.,
    8. Diallo D. A.
    Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56 1997 637 639
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Duncombe V. M.,
    2. Bolin T. D.,
    3. Davis A. E.,
    4. Crouch R. L.
    Histopathology in giardiasis: a correlation with diarrhea. Aust. N. Z. J. Med. 8 1978 392 396
    OpenUrlPubMed
  66. 66.↵
    1. DuPont H. L.,
    2. Capsuto E. G.
    Persistent diarrhea in travelers. Clin. Infect. Dis. 22 1996 124 128
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    1. Durel P.,
    2. Roiron V.,
    3. Siboulet H.,
    4. Borel L. J.
    Systemic treatment of human trichomoniasis with a derivative of nitroimidazole. Br. J. Vener. Dis. 36 1960 21 26
    OpenUrlPubMed
  68. 68.↵
    1. Dutta A. K.,
    2. Phadke M. A.,
    3. Bagade A. C.,
    4. Joshi V.,
    5. Gazder A.,
    6. Biswas T. K.,
    7. Gill H. H.,
    8. Jagota S. C.
    A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Indian J. Pediatr. 61 1994 689 693
    OpenUrlPubMed
  69. 69.↵
    1. Edlind T. D.
    Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: correlation with rRNA structure. Antimicrob. Agents Chemother. 33 1989 484 488
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Edlind T. D.
    Tetracyclines as antiparasitic agents: lipophilic derivatives are highly active against Giardia lamblia in vitro. Antimicrob. Agents Chemother. 33 1989 2144 2145
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Edlind T. D.,
    2. Hang T. L.,
    3. Chakraborty P. R.
    Activity of the anthelminthic benzimidazoles against Giardia intestinalis in vitro. J. Infect. Dis. 162 1990 1408 1411
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.↵
    1. Edwards D. I.
    Nitroimidazole drugs—action and resistance mechanisms. I. Mechanisms of action. J. Antimicrob. Chemother. 31 1993 9 20
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    1. Elliott A. M.,
    2. Klaus B. D.,
    3. North D. S.,
    4. Martin H. P.
    Furazolidone-induced mood disorder during the treatment of refractory giardiasis in a patient with AIDS. Clin. Infect. Dis. 26 1998 1015
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Erlandsen S.,
    2. Sherlock L. A.,
    3. Januschka M.,
    4. Schupp D. G.,
    5. Schaefer F. W. III,
    6. Jakubowski W.,
    7. Bemrick W. J.
    Cross-species transmission of Giardia spp.: inoculation of beavers and muskrats with cysts of human, beaver, mouse, and muskrat origin. Appl. Environ. Microbiol. 54 1988 2777 2785
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    1. Erlandsen S. L.,
    2. Macechko P. T.,
    3. van Keulen H.,
    4. Jarroll E. L.
    Formation of the Giardia cyst wall: studies on extracellular assembly using immunogold labeling and high resolution field emission SEM. J. Eukaryot. Microbiol. 43 1996 416 429
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Erlich J. H.,
    2. Anders R. F.,
    3. Roberts-Thomson I. C.,
    4. Schrader J. W.,
    5. Mitchell G. F.
    An examination of differences in serum antibody specificities and hypersensitivity reactions as contributing factors to chronic infection with the intestinal protozoan parasite, Giardia muris, in mice. Aust. J. Exp. Biol. Med. Sci. 61 1983 599 615
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Ey P. L.,
    2. Bruderer T.,
    3. Wehrli C.,
    4. Kohler P.
    Comparison of genetic groups determined by molecular and immunological analyses of Giardia isolated from animals and humans in Switzerland and Australia. Parasitol. Res. 82 1996 52 60
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    1. Falagas M. E.,
    2. Walker A. M.,
    3. Jick H.,
    4. Ruthazer R.,
    5. Griffith J.,
    6. Snydman D. R.
    Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study. Clin. Infect. Dis. 26 1998 384 388
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Farbey M. D.,
    2. Reynoldson J. A.,
    3. Thompson R. C.
    In vitro drug susceptibility of 29 isolates of Giardia intestinalis from humans as assessed by an adhesion assay. Int. J. Parasitol. 25 1995 593 599
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.
    Reference deleted.
  81. 81.↵
    1. Farthing M. J. G.
    Giardia comes of age: progress in epidemiology, immunology and chemotherapy. J. Antimicrob. Chemother. 30 1992 563 566
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Farthing M. J. G.
    Giardiasis. Gastroenterol. Clin. North Am. 25 1996 493 515
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Farthing M. J. G.
    The molecular pathogenesis of giardiasis. J. Pediatr. Gastroenterol. Nutr. 24 1997 79 88
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Farthing M. J. G.,
    2. Inge P. M. G.
    Antigiardial activity of the bile salt-like solution antibiotic sodium fusidate. J. Antimicrob. Chemother. 17 1986 165 171
    OpenUrlCrossRefPubMedWeb of Science
  85. 85.↵
    1. Farthing M. J. G.,
    2. Inge P. M. G.,
    3. Pearson R. M.
    Effect of d-propranolol on growth and motility of flagellate protozoa. J. Antimicrob. Chemother. 20 1987 519 522
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    1. Farthing M. J. G.,
    2. Mata L.,
    3. Urrutia J. J.,
    4. Kronmal R. A.
    Natural history of Giardia infection of infants and children in rural Guatemala and its impact on physical growth. Am. J. Clin. Nutr. 43 1986 395 405
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Faubert G.
    Immune response to Giardia duodenalis. Clin. Microbiol. Rev. 13 2000 35 54
    OpenUrlAbstract/FREE Full Text
  88. 88.
    Reference deleted.
  89. 89.↵
    1. Garcia L. S.,
    2. Shimizu R. Y.
    Detection of Giardia lamblia and Cryptosporidium parvum antigens in human fecal specimens using the ColorPac combination rapid solid-phase qualitative immunochromatographic assay. J. Clin. Microbiol. 38 2000 1267 1268
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Garcia L. S.,
    2. Shimizu R. Y.
    Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J. Clin. Microbiol. 35 1997 1526 1529
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    1. Garg B. K.
    Furazolidone and metronidazole in the treatment of giardiasis. Indian J. Pediatr. 39 1972 264 266
    OpenUrlPubMed
  92. 92.↵
    1. Gascón J.,
    2. Abós R.,
    3. Valls M. E.,
    4. Corachán M.
    Mebendazole and metronidazole in giardial infections. Trans. R. Soc. Trop. Med. Hyg. 84 1990 694
    OpenUrlPubMed
  93. 93.↵
    1. Gazder A. J.,
    2. Banerjee M.
    Single dose therapy of giardiasis with tinidazole and metronidazole. Drugs 15 1978 S30 S32
    OpenUrlCrossRef
  94. 94.↵
    1. Gillin F. D.,
    2. Diamond L. S.
    Inhibition of clonal growth of Giardia lamblia and Entamoeba histolytica by metronidazole, quinacrine and other antimicrobial agents. J. Antimicrob. Chemother. 8 1981 305 316
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    1. Gillis J. C.,
    2. Wiseman L. R.
    Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 51 1996 621 638
    OpenUrlPubMed
  96. 96.↵
    1. Gilman R. H.,
    2. Miranda E.,
    3. Marquis G. S.,
    4. Vestegui M.,
    5. Martinez H.
    Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community. Lancet i 1988 343 345
    OpenUrl
  97. 97.↵
    1. Goka A. K. J.,
    2. Rolston D. D. K.,
    3. Mathan V. I.,
    4. Farthing M. J. G.
    The relative merits of faecal and duodenal juice microscopy in the diagnosis of giardiasis. Trans. R. Soc. Trop. Med. Hyg. 84 1990 66 67
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Goldman P.
    Metronidazole. N. Engl. J. Med. 303 1980 1212 1218
    OpenUrlPubMedWeb of Science
  99. 99.↵
    1. Goodgame R. W.
    Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Ann. Intern. Med. 124 1996 429 441
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Gorbea Robles M. C.,
    2. Eternod J. G.,
    3. Valázquez F. G.,
    4. et al.
    Estudio comparativo en amebiasis y giardiasis intestinal del lactante y pre-escolar: eficacia y tolerancia del secnidazol vs metronidazol y etofamida. Investig. Med. Int. 16 1989 79 82
    OpenUrl
  101. 101.↵
    1. Gordts B.,
    2. Hemelhof W.,
    3. Asselman C.,
    4. Butzler J. P.
    In vitro susceptibilities of 25 Giardia lamblia isolates of human origin to six commonly used antiprotozoal agents. Antimicrob. Agents Chemother. 28 1985 378 380
    OpenUrlAbstract/FREE Full Text
  102. 102.
    Reference deleted.
  103. 103.↵
    1. Gupta M. C.,
    2. Urrutia J. J.
    Effect of periodic antiascaris and antigiardia treatment on nutritional status of preschool children. Am. J. Clin. Nutr. 36 1982 79 86
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    1. Hall A.,
    2. Nahar Q.
    Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans. R. Soc. Trop. Med. Hyg. 87 1993 84 86
    OpenUrlCrossRefPubMed
  105. 105.↵
    1. Hartman H. R.,
    2. Kyser F. A.
    Giardiasis and its treatment. JAMA 116 1941 2835 2839
    OpenUrlCrossRef
  106. 106.↵
    1. Hartong W. A.,
    2. Gourley W. K.,
    3. Arvanitakis C.
    Giardiasis: clinical spectrum and functional-structural abnormalities of the small intestinal mucosa. Gastroenterology 77 1979 61 69
    OpenUrlPubMed
  107. 107.↵
    1. Heinonen O. P.,
    2. Slone D.,
    3. Shapiro S.
    Birth defects and drugs in pregnancy 1977 296 302 Publishing Sciences Group Littleton, Mass
  108. 108.↵
    1. Herzog D.,
    2. Hammer B.,
    3. Neuweiler J.,
    4. Werder E.
    Chronische Giardiasis mit intestinalem Kleinwuchs and Pubertas tarda bei Immunoglobulinmangelsyndrom: vollstandiges Aufholwachstum nach Therapie. Schweiz. Med. Wochenschr. 128 1998 623 628
    OpenUrlPubMed
  109. 109.↵
    1. Hetsko M. L.,
    2. McCaffery J. M.,
    3. Svard S. G.,
    4. Meng T. C.,
    5. Que X.,
    6. Gillin F. D.
    Cellular and transcriptional changes during excystation of Giardia lamblia in vitro. Exp. Parasitol. 88 1998 172 183
    OpenUrlCrossRefPubMed
  110. 110.↵
    1. Heyworth M. F.
    Immunology of Giardia and Cryptosporidium infections. J. Infect. Dis. 166 1992 465 472
    OpenUrlCrossRefPubMed
  111. 111.↵
    1. Hiatt R. A.,
    2. Markell E. K.,
    3. Ng E.
    How many stool examinations are necessary to detect pathogenic intestinal protozoa? Am. J. Trop. Med. Hyg. 53 1995 36 39
    OpenUrlAbstract/FREE Full Text
  112. 112.↵
    Hill, D. R. Giardia lamblia. In S. H. Gillespie and R. D. Pearson (ed.), Principles and practice of clinical parasitology, in press. John Wiley & Sons, Ltd., Chichester, England.
  113. 113.↵
    1. Hill D. R.
    Giardiasis: Issues in management and treatment. Infect. Dis. Clin. North Am. 7 1993 503 525
    OpenUrlPubMed
  114. 114.↵
    1. Hill D. R.,
    2. Burge J. J.,
    3. Pearson R. D.
    Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum. J. Immunol. 132 1984 2046 2052
    OpenUrlAbstract
  115. 115.↵
    1. Hill D. R.,
    2. Nash T. E.
    Intestinal flagellate and ciliate infections Tropical infectious diseases. Principles, pathogens, & practice Guerrant R. L., Walker D. H., Weller P. F. 1 1999 703 720 Churchill Livingstone Philadelphia, Pa
    OpenUrl
  116. 116.↵
    1. Hill D. R.,
    2. Pohl R.,
    3. Pearson R. D.
    Giardia lamblia: a culture method for determining parasite viability. Am. J. Trop. Med. Hyg. 35 1986 1129 1133
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Inge P. M. G.,
    2. Farthing M. J. G.
    A radiometric assay for antigiardial drugs. Trans. R. Soc. Trop. Med. Hyg. 81 1987 345 347
    OpenUrlCrossRefPubMed
  118. 118.↵
    1. Isaac-Renton J.,
    2. Blatherwick J.,
    3. Bowie W. R.,
    4. Fyfe M.,
    5. Khan M.,
    6. Li A.,
    7. King A.,
    8. McLean M.,
    9. Meed L.,
    10. Moorehead W.,
    11. Ong C. S.,
    12. Robertson W.
    Epidemic and endemic seroprevalence of antibodies to Cryptosporidium and Giardia in residents of three communities with different drinking water supplies. Am. J. Trop. Med. Hyg. 60 1999 578 583
    OpenUrlAbstract
  119. 119.↵
    1. Isaac-Renton J. L.,
    2. Lewis L. F.,
    3. Ong C. S.,
    4. Nulsen M. F.
    A second community outbreak of waterborne giardiasis in Canada and serological investigation of patients. Trans. R. Soc. Trop. Med. Hyg. 88 1994 395 399
    OpenUrlCrossRefPubMed
  120. 120.↵
    1. Isaac-Renton J. L.,
    2. Shahriari H.,
    3. Bowie W. R.
    Comparison of an in vitro method and an in vivo method of Giardia excystation. Appl. Environ. Microbiol. 58 1992 1530 1533
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    1. Ish-Horowicz M.,
    2. Korman S. H.,
    3. Shapiro M.,
    4. Har-Even U.,
    5. Tamir I.,
    6. Strauss N.,
    7. Deckelbaum R. J.
    Asymptomatic giardiasis in children. Pediatr. Infect. Dis. J. 8 1989 773 779
    OpenUrlCrossRefPubMedWeb of Science
  122. 122.↵
    1. Jarroll E. L.,
    2. Bingham A. K.,
    3. Meyer E. A.
    Effect of chlorine on Giardia lamblia cyst viability. Appl. Environ. Microbiol. 41 1981 483 487
    OpenUrlAbstract/FREE Full Text
  123. 123.↵
    1. Jephcott A. E.,
    2. Begg N. T.,
    3. Baker I. A.
    Outbreak of giardiasis associated with mains water in the United Kingdom. Lancet i 1986 730 732
    OpenUrlCrossRef
  124. 124.↵
    1. Johns T.,
    2. Faubert G. M.,
    3. Kokwaro J. O.,
    4. Mahunnah R. L. A.,
    5. Kimanani E. K.
    Anti-giardial activity of gastrointestinal remedies of the Luo of east Africa. J. Ethnopharmacol. 46 1995 17 23
    OpenUrlCrossRefPubMed
  125. 125.↵
    1. Jokipii A. M. M.,
    2. Hemilä M.,
    3. Jokipii L.
    Prospective study of acquisition of cryptosporidium, Giardia lamblia, and gastrointestinal illness. Lancet ii 1985 487 489
    OpenUrlCrossRefPubMedWeb of Science
  126. 126.↵
    1. Jokipii A. M. M.,
    2. Jokipii L.
    Comparative evaluation of two dosages of tinidazole in the treatment of giardiasis. Am. J. Trop. Med. Hyg. 27 1978 758 761
    OpenUrlAbstract/FREE Full Text
  127. 127.↵
    1. Jokipii L.,
    2. Jokipii A. M. M.
    Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. Infection. 6 1978 92 94
    OpenUrlCrossRefPubMed
  128. 128.↵
    1. Jokipii L.,
    2. Jokipii A. M. M.
    Giardiasis in travelers: a prospective study. J. Infect. Dis. 130 1974 295 299
    OpenUrlPubMed
  129. 129.↵
    1. Jokipii L.,
    2. Jokipii A. M. M.
    In vitro susceptibility of Giardia lamblia to metronidazole and tinidazole. J. Infect. Dis. 141 1980 317 325
    OpenUrlCrossRefPubMed
  130. 130.↵
    1. Jokipii L.,
    2. Jokipii A. M. M.
    Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. J. Infect. Dis. 140 1979 984 988
    OpenUrlCrossRefPubMed
  131. 131.↵
    1. Jokipii L.,
    2. Jokipii A. M. M.
    Treatment of giardiasis: comparative evaluation of ornidazole and tinidazole as a single oral dose. Gastroenterology 83 1982 399 404
    OpenUrlPubMed
  132. 132.↵
    1. Kalyci A. G.,
    2. Cetinbkaya F.,
    3. Gunaydin M.,
    4. Gurses N.
    Comparison of mebendazole with metronidazole and furazolidone in the treatment of giardiasis in children. Ann. Saudi Med. 15 1995 655 656
    OpenUrlPubMed
  133. 133.↵
    1. Kang E. W.,
    2. Clinch K.,
    3. Furneaux R. H.,
    4. Harvey J. E.,
    5. Schofield P. J.,
    6. Gero A. M.
    A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro. Parasitology 117 1998 229 234
    OpenUrlCrossRef
  134. 134.↵
    1. Kaucner C.,
    2. Stinear T.
    Sensitive and rapid detection of viable Giardia cysts and Cryptosporidium parvum oocysts in large-volume water samples with wound fiberglass cartridge filters and reverse transcription-PCR. Appl. Environ. Microbiol. 64 1998 1743 1749
    OpenUrlAbstract/FREE Full Text
  135. 135.↵
    1. Kavousi S.
    Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine®) and metronidazole (Flagyl®). Am. J. Trop. Med. Hyg. 28 1979 19 23
    OpenUrlAbstract/FREE Full Text
  136. 136.↵
    1. Kettis A. A.,
    2. Magnius L. G.
    Giardia lamblia infection in a group of students after a visit to Leningrad in March 1970. Scand. J. Infect. Dis. 5 1973 289 292
    OpenUrlPubMed
  137. 137.↵
    1. Kollaritsch H.,
    2. Jeschko E.,
    3. Wiederman G.
    Albendazole is highly effective against cutaneous larva migrans but not against Giardia infection: results of an open pilot trial in travellers returning from the tropics. Trans. R. Soc. Trop. Med. Hyg. 87 1993 689
    OpenUrlCrossRefPubMed
  138. 138.↵
    1. Korman S. H.,
    2. Hais E.,
    3. Spira D. T.
    Routine in vitro cultivation of Giardia lamblia by using the string test. J. Clin. Microbiol. 28 1990 368 369
    OpenUrlAbstract/FREE Full Text
  139. 139.↵
    1. Kramer M. H.,
    2. Herwaldt B. L.,
    3. Craun G. F.,
    4. Calderon R. L.,
    5. Juranek D. D.
    Surveillance for waterborne-disease outbreaks—United States, 1993–1994. CDC Surveillance Summaries, April 12, 1996. Morb. Mortal. Weekly Rep. 45 SS-1 1996 1 30
    OpenUrl
  140. 140.↵
    1. Kreutner A. K.,
    2. Del Bene V. E.,
    3. Amstey M. S.
    Giardiasis in pregnancy. Am. J. Obstet. Gynecol. 140 1981 895 901
    OpenUrlCrossRefPubMedWeb of Science
  141. 141.↵
    1. Kucers A.,
    2. Crowe S. M.,
    3. Grayson M. L.,
    4. Hoy J. F.
    Bacitracin and gramicidin The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral drugs 5th ed. Kucers A., Crowe S. M., Grayson M. L., Hoy J. F. 1997 542 543 Butterworth-Heinemann Oxford, United Kingdom
  142. 142.↵
    1. Kucers A.,
    2. Crowe S. M.,
    3. Grayson M. L.,
    4. Hoy J. F.
    Neomycin, framycetin and paromomycin The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral Drugs 5th ed. Kucers A., Crowe S. M., Grayson M. L., Hoy J. F. 1997 533 541 Butterworth-Heinemann Oxford, United Kingdom
  143. 143.↵
    1. Kucers A.,
    2. Crowe S. M.,
    3. Grayson M. L.,
    4. Hoy J. F.
    Nitrofurans: nitrofurozone, furazolidone and nitrofurantoin The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral drugs 5th ed. Kucers A., Crowe S. M., Grayson M. L., Hoy J. F. 1997 922 923 Butterworth-Heinemann Oxford, United Kingdom
  144. 144.↵
    1. Kusumi R. K.,
    2. Plouffe J. F.,
    3. Wyatt R. H.,
    4. Fass R. J.
    Central nervous system toxicity associated with metronidazole therapy. Ann. Intern. Med. 93 1980 59 60
    OpenUrlPubMedWeb of Science
  145. 145.↵
    1. Kuzmicki R.,
    2. Jeske J.
    Observations of the efficacy of ornidazole (Tiberal La Roche) in treatment of giardiasis. Wiad. Parazytol. 40 1994 65 68
    OpenUrlPubMed
  146. 146.↵
    1. Kyrönseppä H.,
    2. Pettersson T.
    Treatment of giardiasis: relative efficacy of metronidazole as compared with tinidazole. Scand. J. Infect. Dis. 13 1981 311 312
    OpenUrlPubMed
  147. 147.↵
    1. Lau A. H.,
    2. Lam N. P.,
    3. Piscitelli S. C.,
    4. Wilkes L.,
    5. Danzinger L. H.
    Clinical pharmacokinetics of metronidazole and other nitroimidazole anti- infectives. Clin. Pharmacokinet. 23 1992 328 364
    OpenUrlCrossRefPubMed
  148. 148.↵
    1. Laughon B. E.,
    2. Druckman D. A.,
    3. Vernon A.,
    4. Quinn T. C.,
    5. Polk B. F.,
    6. Modlin J. F.,
    7. Yolken R. H.,
    8. Bartlett J. G.
    Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology 94 1988 984 993
    OpenUrlPubMedWeb of Science
  149. 149.↵
    1. Lengerich E. J.,
    2. Addiss D. G.,
    3. Juranek D. D.
    Severe giardiasis in the United States. Clin. Infect. Dis. 18 1994 760 763
    OpenUrlCrossRefPubMed
  150. 150.↵
    1. Lerman S. J.,
    2. Walker R. A.
    Treatment of giardiasis. Literature review and recommendations. Clin. Pediatr. 21 1982 409 414
    OpenUrlCrossRefPubMed
  151. 151.↵
    1. Levi G. C.,
    2. de Avila C. A.,
    3. Neto V. A.
    Efficacy of various drugs for treatment of giardiasis. A comparative study. Am. J. Trop. Med. Hyg. 26 1977 564 565
    OpenUrlAbstract/FREE Full Text
  152. 152.↵
    1. Levine W. C.,
    2. Smart J. F.,
    3. Archer D. L.,
    4. Bean N. H.,
    5. Tauxe R. V.
    Foodborne disease outbreaks in nursing homes, 1975 through 1987. JAMA 266 1991 2105 2109
    OpenUrlCrossRefPubMedWeb of Science
  153. 153.↵
    1. Lindmark D. G.,
    2. Muller M.
    Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob. Agents Chemother. 10 1976 476 482
    OpenUrlAbstract/FREE Full Text
  154. 154.↵
    1. Lindquist H. D.
    Induction of albendazole resistance in Giardia lamblia. Microb. Drug Resist. 2 1996 433 434
    OpenUrlPubMed
  155. 155.↵
    1. Liu L. X.,
    2. Weller P. F.
    Antiparasitic drugs. N. Engl. J. Med. 334 1996 1178 1184
    OpenUrlCrossRefPubMedWeb of Science
  156. 156.↵
    1. Lujan H. D.,
    2. Mowatt M. R.,
    3. Nash T. E.
    Mechanisms of Giardia lamblia differentiation into cysts. Microbiol. Mol. Biol. Rev. 61 1997 294 304
    OpenUrlAbstract/FREE Full Text
  157. 157.↵
    1. MacDonald T. T.,
    2. Spencer J.
    Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J. Exp. Med. 167 1988 1341 1349
    OpenUrlAbstract/FREE Full Text
  158. 158.↵
    1. Mahbubani M. H.,
    2. Schaefer F. W. I.,
    3. Jones D. D.,
    4. Bej A. K.
    Detection of Giardia in environmental waters by immuno-PCR amplification methods. Curr. Microbiol. 36 1998 107 113
    OpenUrlCrossRefPubMed
  159. 159.↵
    1. Mahmud M. A.,
    2. Chappell C.,
    3. Hossain M. M.,
    4. Habib M.,
    5. DuPont H. L.
    Risk factors for development of first symptomatic Giardia infection among infants of a birth cohort in rural Egypt. Am. J. Trop. Med. Hyg. 53 1995 84 88
    OpenUrlAbstract/FREE Full Text
  160. 160.↵
    1. Majewska A. C.,
    2. Kasprzak W.,
    3. De Jonckheere J. F.,
    4. Kaczmarek E.
    Heterogeneity in the sensitivity of stocks and clones of Giardia to metronidazole and ornidazole. Trans. R. Soc. Trop. Med. Hyg. 85 1991 67 69
    OpenUrlCrossRefPubMed
  161. 161.↵
    1. Mank T. G.,
    2. Zaat J. O.,
    3. Deelder A. M.,
    4. van Eijk J. T.,
    5. Polderman A. M.
    Sensitivity of microscopy versus enzyme immunoassay in the laboratory diagnosis of giardiasis. Eur. J. Clin. Microbiol. Infect. Dis. 16 1997 615 619
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.↵
    1. Markell E. K.,
    2. Havens R. F.,
    3. Kuritsubo R. A.,
    4. Wingerd J.
    Intestinal protozoa in homosexual men of the San Francisco Bay area: prevalence and correlates of infection. Am. J. Trop. Med. Hyg. 33 1984 239 245
    OpenUrlAbstract/FREE Full Text
  163. 163.↵
    1. Mata L. J.
    The children of Santa Marı́a Cauqué: a prospective field study of health and growth. 1978 MIT Press Cambridge, Mass
  164. 164.↵
    1. McIntyre P.,
    2. Boreham P. F. L.,
    3. Phillips R. E.,
    4. Shepard R. W.
    Chemotherapy in giardiasis: clinical responses and in vitro drug sensitivity of human isolates in axenic culture. J. Pediatr. 108 1986 1005 1010
    OpenUrlCrossRefPubMedWeb of Science
  165. 164a.↵
    Medical Economics Company, Inc Flagyl Physicians' desk reference 53rd ed. 1999 2961 2963 Medical Economics Co., Inc. Montvale, N.J
  166. 164b.↵
    Medical Economics Company, Inc Furoxone Physicians' desk reference 53rd ed. 1999 2627 Medical Econimics Co., Inc. Montvale, N.J
  167. 165.↵
    1. Meingasser J. G.,
    2. Heyworth P. G.
    Intestinal and urogenital flagellates. Antibiotics Chemother. 30 1981 163 202
    OpenUrl
  168. 166.↵
    1. Meloni B. P.,
    2. Thompson R. C. A.,
    3. Reynoldson J. A.,
    4. Seville P.
    Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans. R. Soc. Trop. Med. Hyg. 84 1990 375 379
    OpenUrlCrossRefPubMedWeb of Science
  169. 167.↵
    1. Meyer E. A.,
    2. Radulescu S.
    Giardia and giardiasis. Adv. Parasitol. 17 1979 1 47
    OpenUrlPubMed
  170. 168.↵
    1. Meyers J. D.,
    2. Kuharic H. A.,
    3. Holmes K. K.
    Giardia lamblia infection in homosexual men. Br. J. Vener. Dis. 53 1977 54 55
    OpenUrlPubMedWeb of Science
  171. 169.↵
    1. Mintz E. D.,
    2. Hudson-Wragg M.,
    3. Mshar P.,
    4. Cartter M. L.,
    5. Hadler J. L.
    Foodborne giardiasis in a corporate office setting. J. Infect. Dis. 167 1993 250 253
    OpenUrlCrossRefPubMed
  172. 170.↵
    1. Miotti P. G.,
    2. Gilman R. H.,
    3. Santosham M.,
    4. Ryder R. W.,
    5. Yolken R. H.
    Age-related rate of seropositivity of antibody to Giardia lamblia in four diverse populations. J. Clin. Microbiol. 24 1986 972 975
    OpenUrlAbstract/FREE Full Text
  173. 171.↵
    1. Misra P. K.,
    2. Kumar A.,
    3. Agarwal V.,
    4. Jagota S. C.
    A comparative trial of albendazole versus metronidazole in children with giardiasis. Indian Pediatr. 32 1995 779 782
    OpenUrlPubMed
  174. 172.↵
    1. Miyares C.,
    2. Hollands I.,
    3. Castaneda C.,
    4. Gonzalez T.,
    5. Fragaso T.,
    6. Curras R.,
    7. Soria C.
    Ensayo terapeutica con un preparado a base de propoleo “propolisina” en la giardiasis del humano. Acta Gastroenterol. Latinoam. 18 1988 195 201
    OpenUrlPubMed
  175. 173.↵
    1. Monis P. T.,
    2. Mayrhofer G.,
    3. Andrews R. H.,
    4. Homan W. L.,
    5. Limper L.,
    6. Ey P. L.
    Molecular genetic analysis of Giardia intestinalis isolates at the glutamate dehydrogenase locus. Parasitology 112 1996 1 12
    OpenUrlCrossRefPubMedWeb of Science
  176. 174.↵
    1. Moore G. T.,
    2. Cross W. M.,
    3. McGuire D.,
    4. Mollohan C. S.,
    5. Gleason N. N.,
    6. Healy G. R.,
    7. Newton L. H.
    Epidemic giardiasis at a ski resort. N. Engl. J. Med. 281 1969 402 407
    OpenUrlPubMedWeb of Science
  177. 175.↵
    1. Morgan U. M.,
    2. Reynoldson J. A.,
    3. Thompson R. C.
    Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro. Antimicrob. Agents Chemother. 37 1993 328 331
    OpenUrlAbstract/FREE Full Text
  178. 176.↵
    1. Morrow A. L.,
    2. Reves R. R.,
    3. West M. S.,
    4. Guerrero M. L.,
    5. Ruiz-Palacios G. M.,
    6. Pickering L. K.
    Protection against infection with Giardia lamblia by breast feeding in a cohort of Mexican infants. J. Pediatr. 121 1992 363 370
    OpenUrlCrossRefPubMedWeb of Science
  179. 177.↵
    1. Muller M.
    Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 93 1983 165 171
    OpenUrlPubMedWeb of Science
  180. 178.↵
    1. Murphy T. V.,
    2. Nelson J. D.
    Five vs. ten days' therapy with furazolidone for giardiasis. Am. J. Dis. Child. 137 1983 267 270
    OpenUrlCrossRefPubMed
  181. 179.↵
    1. Namgung R.,
    2. Ryu J. S.,
    3. Lee K. T.,
    4. Soh C. T.
    The effect of metronidazole and quinacrine on the morphology and the excystation of Giardia lamblia. Yonsei Rep. Trop. Med. 16 1985 28 44
    OpenUrl
  182. 180.↵
    1. Nash T.,
    2. Rice W. G.
    Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob. Agents Chemother. 42 1998 1488 1492
    OpenUrlAbstract/FREE Full Text
  183. 181.↵
    1. Nash T. E.
    Antigenic variation in Giardia lamblia and the host's immune response. Philos. Trans. R. Soc. London Ser. B. 352 1997 1369 1375
    OpenUrlCrossRefPubMedWeb of Science
  184. 182.↵
    1. Nash T. E.,
    2. Herrington D. A.,
    3. Losonsky G. A.,
    4. Levine M. M.
    Experimental human infections with Giardia lamblia. J. Infect. Dis. 156 1987 974 984
    OpenUrlCrossRefPubMedWeb of Science
  185. 182a.↵
    Nash, T. E., C. A. Ohl, E. Thomas, G. Subramanian, P. Keiser, and T. Moore. Treatment of refractory giardiasis. Clin. Infect. Dis., in press.
  186. 183.↵
    1. Nayak N.,
    2. Ganguly N. K.,
    3. Walia B. N. S.,
    4. Wahi V.,
    5. Kanwar S. S.,
    6. Mahajan R. C.
    Specific secretory IgA in the milk of Giardia lamblia-infected and uninfected women. J. Infect. Dis. 155 1987 724 727
    OpenUrlCrossRefPubMedWeb of Science
  187. 184.↵
    1. Notis W. M.
    Giardiasis and vitamin B12 malabsorption. Gastroenterology 63 1972 1085
    OpenUrlPubMed
  188. 185.↵
    1. Oberhuber G.,
    2. Kastner N.,
    3. Stolte M.
    Giardiasis: a histologic analysis of 567 cases. Scand. J. Infect. Dis. 32 1997 48 51
    OpenUrl
  189. 186.↵
    1. Oren B.,
    2. Schgurensky E.,
    3. Ephros M.,
    4. Tamir I.,
    5. Raz R.
    Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel. Eur. J. Clin. Microbiol. Infect. Dis. 10 1991 963 965
    OpenUrlCrossRefPubMed
  190. 187.↵
    1. Osterholm M. T.,
    2. Forfang J. C.,
    3. Ristinen T. L.,
    4. Dean A. G.,
    5. Washburn J. W.,
    6. Godes J. R.,
    7. Rude R. A.,
    8. McCullough J. G.
    An outbreak of foodborne giardiasis. N. Engl. J. Med. 304 1981 24 28
    OpenUrlPubMedWeb of Science
  191. 188.
    Reference deleted.
  192. 189.↵
    1. Paget T. A.,
    2. Jarroll E. L.,
    3. Manning P.,
    4. Lindmark D. G.,
    5. Lloyd D.
    Respiration in the cysts and trophozoites of Giardia muris. J. Gen. Microbiol. 135 1989 145 154
    OpenUrlCrossRefPubMed
  193. 190.↵
    1. Paintlia A. S.,
    2. Descoteaux S.,
    3. Spencer B.,
    4. Chakraborti A.,
    5. Ganguly N. K.,
    6. Mahajan R. C.,
    7. Samuelson J.
    Giardia lamblia groups A and B among young adults in India. Clin. Infect. Dis. 26 1998 190 191
    OpenUrlCrossRefPubMedWeb of Science
  194. 191.↵
    1. Palomino H.,
    2. Pérez C.,
    3. Donckaster R.,
    4. Sapunar J.,
    5. Gabor M.,
    6. Atı́as A.,
    7. Parodi V.,
    8. Narbona L.
    Ensayo terapéutico con cinco medicamentos en lambliasis. Bol. Chil. Parasitol. 25 1970 52 56
    OpenUrlPubMed
  195. 192.↵
    1. Pearce D. A.,
    2. Reynoldson J. A.,
    3. Thompson R. C.
    A comparison of two methods for assessing drug sensitivity in Giardia duodenalis. Appl. Parasitol. 37 1996 111 116
    OpenUrlPubMed
  196. 193.↵
    1. Pengsaa K.,
    2. Sirivichayakul C.,
    3. Pojjaroen-anant C.,
    4. Nimnual S.,
    5. Wisetsing P.
    Albendazole treatment of Giardia intestinalis infections in school children. S. Asian J. Trop. Med. Public Health 30 1999 78 83
    OpenUrlPubMed
  197. 194.
    Reference deleted.
  198. 195.↵
    1. Pickering L. K.,
    2. Woodward W. E.,
    3. DuPont H. L.,
    4. Sullivan P.
    Occurrence of Giardia lamblia in children in day care centers. J. Pediatr. 104 1984 522 526
    OpenUrlCrossRefPubMedWeb of Science
  199. 196.↵
    1. Polis M. A.,
    2. Tuazon C. U.,
    3. Alling D. W.,
    4. Talamis E.
    Transmission of Giardia lamblia from a day care center to the community. Am. J. Public Health 76 1986 1142 1144
    OpenUrlPubMedWeb of Science
  200. 197.↵
    1. Popovic O. S.,
    2. Milovic V.
    Propranolol and metronidazole for the treatment of metronidazole-resistant giardiasis. J. Clin. Gastroenterol. 12 1990 604 605
    OpenUrlCrossRefPubMedWeb of Science
  201. 198.↵
    1. Pungpak S.,
    2. Singhasivanon V.,
    3. Bunnag D.,
    4. Radomyos B.,
    5. Nibaddhasopon P.,
    6. Harinasuta K. T.
    Albendazole as a treatment for Giardia infection. Ann. Trop. Med. Parasitol. 90 1996 563 565
    OpenUrlPubMed
  202. 199.↵
    1. Quick R.,
    2. Paugh K.,
    3. Addiss D.,
    4. Kobayashi J.,
    5. Baron R.
    Restaurant-associated outbreak of giardiasis. J. Infect. Dis. 166 1992 673 676
    OpenUrlCrossRefPubMed
  203. 200.↵
    1. Quinn T. C.,
    2. Stamm W. E.,
    3. Goodell S. E.,
    4. Mkrtichian E.,
    5. Benedetti J.,
    6. Corey L.,
    7. Schuffler M. D.,
    8. Holmes K. K.
    The polymicrobial origin of intestinal infections in homosexual men. N. Engl. J. Med. 309 1983 576 582
    OpenUrlCrossRefPubMedWeb of Science
  204. 201.↵
    1. Quiros-Buelna E.
    Furazolidone and metronidazole for treatment of giardiasis in children. Scand. J. Gastroenterol. 169 1989 S65 S69
    OpenUrl
  205. 202.↵
    Reference deleted.
  206. 203.↵
    1. Rauch A. M.,
    2. Rory V. M. T.,
    3. Bartlett A. V.,
    4. Pickering L. K.
    Longitudinal study of Giardia lamblia infection in a day care center population. Pediatr. Infect. Dis. J. 9 1990 186 189
    OpenUrlCrossRefPubMedWeb of Science
  207. 204.↵
    1. Reiner D. S.,
    2. Wang C. S.,
    3. Gillin F. D.
    Human milk kills Giardia lamblia by generating toxic lipolytic products. J. Infect. Dis. 154 1986 825 832
    OpenUrlCrossRefPubMed
  208. 205.↵
    1. Reinthaler F. F.,
    2. Feierl G.,
    3. Stunzner D.,
    4. Marth E.
    Diarrhea in returning Austrian tourists: epidemiology, etiology, and cost-analysis. J. Travel Med. 5 1998 65 72
    OpenUrlCrossRefPubMed
  209. 206.↵
    1. Rendtorff R. C.
    The experimental transmission of human intestinal protozoan parasites. II. Giardia lamblia cysts given in capsules. Am. J. Hyg. 59 1954 209 220
    OpenUrlPubMedWeb of Science
  210. 207.↵
    1. Reynoldson J. A.,
    2. Behnke J. M.,
    3. Gracey M.,
    4. Horton R. J.,
    5. Spargo R.,
    6. Hopkins R. M.,
    7. Constantine C. C.,
    8. Gilbert F.,
    9. Stead C.,
    10. Hobbs R. P.,
    11. Thompson R. C.
    Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. Acta Trop. 71 1998 27 44
    OpenUrlCrossRefPubMedWeb of Science
  211. 208.↵
    1. Reynoldson J. A.,
    2. Thompson R. C. A.,
    3. Horton R. J.
    Albendazole as a future antigiardial agent. Parasitol. Today 8 1992 412 414
    OpenUrlPubMed
  212. 209.↵
    1. Reynoldson J. A.,
    2. Thompson R. C. A.,
    3. Meloni B. P.
    The mode of action of benzimidazoles against Giardia and their chemotherapeutic potential against Giardia and other parasitic protozoa Biochemical protozoology. Coombs G. H., North M. J. 1991 587 593 Taylor & Francis Ltd. London, United Kingdom
  213. 210.↵
    1. Rice E. W.,
    2. Schaefer F. W.
    Improved in vitro excystation procedure for Giardia lamblia cysts. J. Clin. Microbiol. 14 1981 709 710
    OpenUrlAbstract/FREE Full Text
  214. 211.↵
    1. Rodriguez-Garcia R.,
    2. Rodriguez-Guzman L. M.,
    3. Cruz del Castillo A. H.
    Eficacia y seguridad de mebendazol contra nitazoxanida en el tratamiento de Giardia lamblia en niños. Rev. Gastroenterol. Mex. 64 1999 122 126
    OpenUrlPubMed
  215. 212.↵
    1. Roe F. J. C.
    Safety of nitroimidazoles. Scand. J. Infect. Dis. 46 1985 72 81
    OpenUrl
  216. 213.
    1. Romero Cabello R.,
    2. Guerrero L. R.,
    3. Muñóz Garcı́a M. R.,
    4. Geyne Cruz A.
    Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91 1997 701 703
    OpenUrlCrossRefPubMedWeb of Science
  217. 214.↵
    1. Romero-Cabello R.,
    2. Robert L.,
    3. Muñoz-Garcia R.,
    4. Tanaka J.
    Estudio aleatorio para comparar seguridad y eficacia de albendazol y metronidazol en el tratamiento de giardiasis en niños. Rev. Latinoam. Microbiol. 37 1995 315 323
    OpenUrlPubMed
  218. 215.↵
    1. Rosa F. W.,
    2. Baum C.,
    3. Shaw M.
    Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet. Gynecol. 69 1987 751 755
    OpenUrlPubMedWeb of Science
  219. 216.↵
    1. Rosen F. S.,
    2. Cooper M. D.,
    3. Wedgwood R. J. P.
    The primary immunodeficiencies. N. Engl. J. Med. 333 1995 431 440
    OpenUrlCrossRefPubMedWeb of Science
  220. 217.↵
    1. Rossignol J. F.,
    2. Maisonneuve H.,
    3. Cho Y. W.
    Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int. J. Clin. Pharmacol. Ther. Toxicol. 22 1984 63 72
    OpenUrlPubMed
  221. 218.↵
    1. Rotblatt M. D.
    Giardiasis and amebiasis in pregnancy. Drug Intell. Clin. Pharm. 17 1983 187 188
    OpenUrl
  222. 219.↵
    1. Rousham E. K.
    An increase in Giardia duodenalis infection among children receiving periodic anthelminthic treatment in Bangladesh. J. Trop. Pediatr. 40 1994 329 333
    OpenUrlCrossRefPubMedWeb of Science
  223. 220.↵
    1. Sabchareon A.,
    2. Chongsuphajaisiddhi T.,
    3. Attanath P.
    Treatment of giardiasis in children with quinacrine, metronidazole, tinidazole and ornidazole. S. Asian J. Trop. Med. Public Health 11 1980 280 284
    OpenUrlPubMed
  224. 221.↵
    1. Sagi E. F.,
    2. Shapiro M.,
    3. Deckelbaum R. J.
    Giardia lamblia: prevalence, influence on growth, and symptomatology in healthy nursery children. Isr. J. Med. Sci. 19 1983 815 817
    OpenUrl
  225. 222.↵
    1. Salih S. Y.,
    2. Abdalla R. E.
    Symptomatic giardiasis in Sudanese adults and its treatment with tinidazole. J. Trop. Med. Hyg. 80 1977 11 13
    OpenUrlPubMed
  226. 223.↵
    1. Samuelson J.
    Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother. 43 1999 1533 1541
    OpenUrlFREE Full Text
  227. 224.↵
    1. Sealy D. P.,
    2. Schuman S. H.
    Endemic giardiasis and day care. Pediatrics 72 1983 154 158
    OpenUrlAbstract/FREE Full Text
  228. 225.↵
    1. Smith P. D.,
    2. Gillin F. D.,
    3. Spira W. M.,
    4. Nash T. E.
    Chronic giardiasis: studies on drug sensitivity, toxin production, and host immune response. Gastroenterology 83 1982 797 803
    OpenUrlPubMedWeb of Science
  229. 226.↵
    1. Smith P. D.,
    2. Quinn T. C.,
    3. Strober W.,
    4. Janoff E. N.,
    5. Masur H.
    Gasirointestinal infections in AIDS. Ann. Intern. Med. 116 1992 63 77
    OpenUrlCrossRefPubMedWeb of Science
  230. 227.↵
    1. Solomons N. W.
    Giardiasis: nutritional implications. Rev. Infect. Dis. 4 1982 859 869
    OpenUrlPubMedWeb of Science
  231. 228.↵
    1. Sousa M. C.,
    2. Poiares-da-Silva J.
    A new method for assessing metronidazole susceptibility of Giardia lamblia trophozoites. Antimicrob. Agents Chemother. 43 1999 2939 2942
    OpenUrlAbstract/FREE Full Text
  232. 229.↵
    1. Speelman P.
    Single-dose tinidazole for the treatment of giardiasis. Antimicrob. Agents Chemother. 27 1985 227 229
    OpenUrlAbstract/FREE Full Text
  233. 230.↵
    1. Steketee R. W.,
    2. Reid S.,
    3. Cheng T.,
    4. Stoebig J. S.,
    5. Harrington R. G.,
    6. Davis J. P.
    Recurrent outbreaks of giardiasis in a child care center, Wisconsin. Am. J. Public Health 79 1989 485 490
    OpenUrlCrossRefPubMedWeb of Science
  234. 231.↵
    1. Sullivan P. S.,
    2. DuPont H. L.,
    3. Arafat R. R.,
    4. Thornton S. A.,
    5. Selwyn B. J.,
    6. El Alamy M. A.,
    7. Zaki A. M.
    Illness and reservoirs associated with Giardia lamblia infection in rural Egypt: the case against treatment in developing world environments of high endemicity. Am. J. Epidemiol. 127 1988 1272 1281
    OpenUrlPubMedWeb of Science
  235. 232.↵
    1. Suntornpoch V.,
    2. Chavalittamrong B.
    Treatment of giardiasis in children with tinidazole, ornidazole and metronidazole. S. Asian J. Trop. Med. Public Health 12 1981 231 235
    OpenUrl
  236. 233.↵
    1. Takeuchi T.,
    2. Kobayashi S.,
    3. Tanabe M.,
    4. Fujiwara T.
    In vitro inhibition of Giardia lamblia and Trichomonas vaginalis growth by bithionol, dichlorophene, and hexachlorophene. Antimicrob. Agents Chemother. 27 1985 65 70
    OpenUrlAbstract/FREE Full Text
  237. 234.↵
    1. Taylor G. D.,
    2. Wenman W. M.,
    3. Tyrrell D. L. J.
    Combined metronidazole and quinacrine hydrochloride therapy for chronic giardiasis. Can. Med. Assoc. J. 136 1987 1179 1180
    OpenUrlPubMed
  238. 235.↵
    1. Thiriat L.,
    2. Sidaner F.,
    3. Schwartzbrod J.
    Determination of Giardia cyst viability in environmental and faecal samples by immunofluorescence, fluorogenic dye staining and differential interference microscopy. Lett. Appl. Microbiol. 26 1998 237 242
    OpenUrlCrossRefPubMed
  239. 236.↵
    1. Thompson R. C. A.,
    2. Reynoldson J. A.,
    3. Mendis A. H.
    Giardia and giardiasis. Adv. Parasitol. 32 1993 71 160
    OpenUrlCrossRefPubMedWeb of Science
  240. 237.↵
    1. Thompson S. C.
    Giardia lamblia in children and the child care setting: a review of the literature. J. Paediatr. Child Health 30 1994 202 209
    OpenUrlPubMedWeb of Science
  241. 238.↵
    1. Townson S. M.,
    2. Hanson G. R.,
    3. Upcroft J. A.,
    4. Upcroft P.
    A purified ferredoxin from Giardia duodenalis. Eur. J. Biochem. 220 1994 439 446
    OpenUrlPubMedWeb of Science
  242. 239.↵
    1. Townson S. M.,
    2. Upcroft J. A.,
    3. Upcroft P.
    Characterization and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis. Mol. Biochem. Parasitol. 79 1996 183 193
    OpenUrlCrossRefPubMedWeb of Science
  243. 240.↵
    1. Tracy J. W.,
    2. Webster L. T.
    Drugs used in the chemotherapy of protozoal infections The pharmacological basis of therapeutics 9th ed. Hardman J. G., Limbird L. E. 1996 987 1008 McGraw-Hill Book Co. New York, N.Y
  244. 241.↵
    1. Tripathi D. M.,
    2. Gupta N.,
    3. Lakshmi V.,
    4. Saxena K. C.,
    5. Agrawal A. K.
    Antigiardial and immunostimulatory effect of Piper longum on giardiasis due to Giardia lamblia. Phytother. Res. 13 1999 561 565
    OpenUrlCrossRefPubMed
  245. 242.↵
    1. Underdown B. J.,
    2. Roberts-Thomson I. C.,
    3. Anders R. F.,
    4. Mitchell G. F.
    Giardiasis in mice: studies on the characteristics of chronic infection in C3H/He mice. J. Immunol. 126 1981 669 672
    OpenUrlAbstract/FREE Full Text
  246. 243.↵
    1. Upcroft J.,
    2. Mitchell R.,
    3. Chen N.,
    4. Upcroft P.
    Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microb. Drug Resist. 2 1996 303 308
    OpenUrlPubMed
  247. 244.↵
    1. Upcroft J.,
    2. Upcroft P.
    My favorite cell: Giardia. Bioessays 20 1998 256 263
    OpenUrlCrossRefPubMedWeb of Science
  248. 245.↵
    1. Upcroft J. A.,
    2. Campbell R. W.,
    3. Benkali K.,
    4. Upcroft P.,
    5. Vanelle P.
    Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother. 43 1999 73 76
    OpenUrlAbstract/FREE Full Text
  249. 246.↵
    1. Upcroft J. A.,
    2. Campbell R. W.,
    3. Upcroft P.
    Quinacrine-resistant Giardia duodenalis. Parasitology 112 1996 309 313
    OpenUrlCrossRefPubMed
  250. 247.↵
    1. Upcroft J. A.,
    2. Upcroft P.
    Drug resistance and Giardia. Parasitol. Today 9 1993 187 190
    OpenUrlCrossRefPubMedWeb of Science
  251. 248.↵
    1. Upcroft J. A.,
    2. Upcroft P.
    Two distinct varieties of Giardia in a mixed infection from a single human patient. J. Eukaryot. Microbiol. 41 1994 189 194
    OpenUrlCrossRefPubMed
  252. 249.↵
    1. Upcroft J. A.,
    2. Upcroft P.,
    3. Boreham P. F. L.
    Drug resistance in Giardia intestinalis. Int. J. Parasitol. 20 1990 489 496
    OpenUrlCrossRefPubMedWeb of Science
  253. 250.↵
    1. Venkatesan P.
    Albendazole. J. Antimicrob. Chemother. 41 1998 145 147
    OpenUrlCrossRefPubMedWeb of Science
  254. 251.↵
    1. Voogd C. E.
    On the mutagenicity of nitroimidazoles. Mutag. Res. 86 1981 243 277
    OpenUrl
  255. 252.↵
    1. Ward W.,
    2. Alvarado L.,
    3. Rawlings N. D.,
    4. Engel J. C.,
    5. Franklin C.,
    6. McKerrow J. H.
    A primitive enzyme for a primitive cell: the protease required for excystation of Giardia. Cell 89 1997 437 444
    OpenUrlCrossRefPubMedWeb of Science
  256. 253.↵
    1. Webster B. H.
    Furazolidone in the treatment of giardiasis. Am. J. Dig. Dis. 5 1960 618 622
    OpenUrlPubMed
  257. 254.↵
    1. Wolfe M. S.
    Giardiasis. Pediatr. Clin. North. Am. 26 1979 295 303
    OpenUrlPubMedWeb of Science
  258. 255.↵
    1. Wolfe M. S.
    Giardiasis. JAMA 233 1975 1362 1365
    OpenUrlCrossRefPubMedWeb of Science
  259. 256.↵
    1. Wolfe M. S.
    Giardiasis. Clin. Microbiol. Rev. 5 1992 93 100
    OpenUrlAbstract/FREE Full Text
  260. 257.↵
    1. Woo P. K.
    Evidence for animal reservoirs and transmission of Giardia infection between animal species Giardia and giardiasis. Erlandsen S. L., Meyer E. A. 1984 341 364 Plenum Press New York, N.Y
  261. 258.↵
    World Health Organization Informal Working Group on Echinococcosis Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull. W. H. O. 74 1996 231 242
    OpenUrlPubMedWeb of Science
  262. 259.↵
    1. Yardley J. H.,
    2. Takano J.,
    3. Hendrix T. R.
    Epithelial and other mucosal lesions of the jejunum in giardiasis. Jejunal biopsy studies. Bull. Johns Hopkins Hosp. 115 1964 389 406
    OpenUrlPubMedWeb of Science
  263. 260.↵
    1. Youssef M. Y. M.,
    2. Essa M. M.,
    3. Sadaka H. A. H.,
    4. Eissa M. M.,
    5. Rizk A. M.
    Effect of ivermectin on combined intestinal protozoal infection (giardiasis and cryptosporidiosis). J. Egypt. Soc. Parasitol. 26 1996 543 553
    OpenUrlPubMed
  264. 261.↵
    1. Zaat J. O.,
    2. Mank T. G.,
    3. Assendelft W. J.
    A systematic review on the treatment of giardiasis. Trop. Med. Int. Health 2 1997 63 82
    OpenUrlCrossRefPubMedWeb of Science
  265. 262.↵
    1. Zimmerman S. K.,
    2. Needham C. A.
    Comparison of conventional stool concentration and preserved-smear methods with Merifluor Cryptosporidium/Giardia Direct Immunofluorescence Assay and ProSpecT Giardia EZ Microplate Assay for the detection of Giardia lamblia. J. Clin. Microbiol. 33 1995 1942 1943
    OpenUrlAbstract/FREE Full Text
  266. 263.↵
    1. Ziv G.,
    2. Sulman F. G.
    Distribution of aminoglycoside antibiotics in blood and milk. Res. Vet. Sci. 17 1974 68 74
    OpenUrlPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Treatment of Giardiasis
Timothy B. Gardner, David R. Hill
Clinical Microbiology Reviews Jan 2001, 14 (1) 114-128; DOI: 10.1128/CMR.14.1.114-128.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Clinical Microbiology Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of Giardiasis
(Your Name) has forwarded a page to you from Clinical Microbiology Reviews
(Your Name) thought you would be interested in this article in Clinical Microbiology Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Treatment of Giardiasis
Timothy B. Gardner, David R. Hill
Clinical Microbiology Reviews Jan 2001, 14 (1) 114-128; DOI: 10.1128/CMR.14.1.114-128.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • SUMMARY
    • BACKGROUND
    • THERAPY OF GIARDIASIS
    • RECOMMENDATIONS
    • ACKNOWLEDGMENT
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antiprotozoal Agents
Giardiasis
Pregnancy Complications, Parasitic

Related Articles

Cited By...

About

  • About CMR
  • Editor in Chief
  • Editorial Board
  • Policies
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Ethics
  • Contact Us

Follow #ClinMicroRev

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0893-8512; Online ISSN: 1098-6618